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1. Introduction 
Human Immunodeficiency Virus (HIV) is the causative agent of Acquired 
Immunodeficiency Syndrome (AIDS) and was first isolated in 1983. It caused severe 
deterioration of the immune system. These are transforming viruses belonging to the 
family Retroviridae and genus lentivirus. Human immunodeficiency virus is of two 
types – HIV-1 and HIV-2. Simian Immunodeficiency virus (SIV) is thought to have 
crossed species barrier from chimpanzees and sooty mangabeys to human beings 
resulting in HIV-1 and HIV-2 respectively. The sequence homology between HIV-1 
and HIV-2 is about 40-60%(1).   
 HIV is a major health issue worldwide. According to WHO, 36.7 million people are 
living with HIV worldwide. In 2015, 1.1 million people have died from HIV related 
causes worldwide(2). Among the people living with HIV about 0.8% are adults 
belonging to age group 15-49 years (3). The newly infected individuals with HIV were 
about 2.1 million globally. Sub-Saharan Africa ranked first with 25.6 million people 
living with HIV that is 70% of the global burden. Two thirds of the total new HIV 
infections in the world are in Sub-Saharan Africa (2). People living with HIV in Asia 
and the Pacific accounted for 5.1 million. There is an estimate of 300,000 new HIV 
infections in this region(4). In Southeast Asia, the prevalence of HIV infections in adults 
was 0.26% (3). New HIV infections have decreased by 35%. Death due to AIDS related 
causes have decreased by 28% between 2000 and 2015(2). Towards end of 2015, 17 
million people living with HIV were receiving antiretroviral therapy (ART) 
worldwide(2). 
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India ranks third in the world with people living with HIV after South Africa and 
Nigeria(5). As per India HIV Estimation 2015 report, HIV adult (15-49 years) 
prevalence in India is 0.26%. Because of India’s large population this equated to around 
2.1 million people living with HIV in 2015. Among the states and union territories, 
Manipur had the highest adult HIV prevalence of 1.15%, Mizoram (0.80%) second in 
line and followed by Nagaland (0.78%), Andhra Pradesh & Telangana, Karnataka,  and 
Gujarat (6,7). Andhra Pradesh &Telangana have the highest estimated number (0.3 
million) of HIV infected individuals followed by Maharashtra, Karnataka, Gujarat, 
Bihar and Uttar Pradesh. These states account for two thirds (64.4%) of total estimated 
people living with HIV. According to HIV Sentinel Surveillance 2014-15, the 
prevalence of HIV in ANC clinic attendees continues to be low at 0.29%. The highest 
prevalence was seen in Nagaland (1.29%) followed by Manipur, Gujarat and 
Chhattisgarh(8). 
According to the National Integrated Behavioural and Biological Surveillance (IBBS) 
2014-2015 report, among the high risk groups – Intravenous drug abusers had the 
highest HIV prevalence of 9.9% followed by MSM 4.3% and Female Sex Workers 
2.2% (9).  
The various modes of transmission of HIV is sexual, parenteral by exposure to infected 
body fluids and from mother to child(2). HIV-1 targets a subset of T lymphocytes 
known as the CD4+T helper cells which serves as receptor for the virus. Entry of the 
virus into the T helper cells is followed by rapid and persistent replication. This results 
in dysfunction and depletion of CD4+T cell by various direct and indirect mechanisms. 
Most of the symptoms are due to decreased or weakened immunity(10). Once the 
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individual is infected the body starts producing antibodies against HIV-1. It is estimated 
that 50-70% of HIV infected individuals experience an acute syndrome approximately 
at 3-6 weeks of infection. Clinical latency is the period during which HIV infected 
individuals do not have any clinical symptoms. Clinical latency is defined as the time 
period from initial infection to the development of clinical disease and differs in 
different individuals. The median time for untreated HIV infected individual is 10 years. 
If an HIV infected individual has high levels of HIV RNA in plasma, they develop 
symptomatic disease faster than those individuals with low levels of HIV RNA. Thus 
comes the importance of an early detection(11).  
HIV incidence is known as the rate at which a population acquires HIV infection and it 
can be used to measure the extent of current HIV transmission in the community(12). 
It is important for partner notification, to establish the incubation period, 
epidemiological surveillance. One of the methods of estimating the incidence is using 
laboratory tests for recent infection. Laboratory based are recommended to estimate 
HIV-1 incidence in cross sectional studies(13). This method provides direct measure of 
incidence and does not require repeated testing(14). Laboratory methods avoids the 
limitations of prospective studies such as bias, high cost and logistics.  
Recent infection is the state that starts when an individual is infected with HIV for the 
first time and biological process of HIV infection is initiated. The duration of recent 
infection is usually defined as 6 months after initiation of the infection for first time. 
Test for Recent HIV Infection (TRI) is defined as a laboratory test used to classify HIV 
infection as long term or recent HIV infection. Many different assays have been 
developed as Tests for Recent HIV Infections. Some of these assays are developed just 
  
4 
 
for identifying recent HIV infections while others are commercial assays used for HIV 
diagnosis which have been modified to identify recent infection. Avidity testing is based 
on fact that evolution and maturation of specific antibodies to HIV-1 occur within first 
two years of seroconversion. Avidity is defined as the strength of antigen-antibody 
binding when several epitopes on an antigen interact with several binding sites of an 
antibody and is known as the binding capacity of a maturing antibody to an antigen. 
The avidity of an antibody increases over time(15). The HIV-1 limiting antigen avidity 
enzyme immunoassay (LAg-Avidity EIA) is a quantitative avidity assay for 
differentiating recent HIV-1 infections from long-term HIV-1 infection. Individuals 
with recent HIV-1 infections have HIV-1 IgG with lower avidity compared to 
antibodies in HIV-1 infected individuals with long-term infections(16). This assay is 
based on the observation that when an individual is exposed to HIV-1 virus, the immune 
system initially produces HIV-1 antibodies with low avidity, and with progression of 
time, the immune system matures and produces HIV-1 antibodies with high avidity. 
More the amount of IgG antibodies with high avidity, the infection is more long term. 
The limiting antigen avidity assay is based on the principle that at high concentrations 
of antigen, antibodies with low avidity and antibodies with high avidity both can bind 
and because of the high density of antigen, the binding can occur with both binding sites 
of the antibodies. When the concentration of the antigen coated is lowered it permits 
the binding of only high avidity antibodies. Moreover, limiting the concentration of 
antigen prevents the binding with two sites simultaneously, so that the antibodies with 
low avidity will not be able to bind strongly to antigen. So based on this method we 
may be able to differentiate long term and recent infections(16). Studies show impaired 
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maturation and production of humoral immune response when HIV-1 infected 
individuals are treated early with antiretroviral therapy (ART)(17). When there is viral 
breakthrough that is the viral load is above 1000/ml in individuals who were on ART, 
the immune system reacts by increasing the proportion of HIV-1 specific antibody 
which may show changes in some of the tests for recent infection(18). 
The main aim of this study was to determine the frequency of recent HIV-1 infections 
among the volunteers who attended the Integrated Counselling and Training Centre 
(ICTC) of a tertiary care centre by quantitative detection of matured HIV-1 IgG 
antibody levels using Limiting Antigen Avidity Enzyme Immunoassay (LAg Avidity 
EIA). We planned to compare the results obtained in LAg avidity assay with an in-
house avidity assay and with the antibody pattern obtained in Western Blot. Also to 
study the avidity maturation of HIV-1 immunoglobulin among HIV-1 infected 
individuals on antiretroviral therapy (ART) using the LAg avidity assay. 
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2. Hypothesis and Objectives 
Hypothesis 
The Limiting antigen avidity assay is a useful technique to determine the quantity of 
matured immunoglobulin (IgG) to identify recent HIV-1 infection and ART leads to an 
impaired production and maturation of IgG in HIV-1 infected individuals. 
 
Objectives 
1. To determine the frequency of recent HIV-1 infections among the volunteers 
who attended the ICTC of CMC hospital by quantitative detection of matured 
HIV-1 IgG antibody levels using LAg avidity assay.  
2. To compare the performance of LAg avidity assay with an in-house avidity 
HIV-1 antibody assay 
3. To compare the normalized OD results obtained in the LAg avidity assay 
with HIV Western Blot antibody pattern to different antigens 
4. To study the impact of antiretroviral therapy on avidity maturation of HIV-1 
specific antibodies among HIV-1 infected individuals 
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3. Literature Review 
3.1. History 
Acquired immunodeficiency syndrome was recognized in US in 1981 when there were 
reports of pneumonia associated with rare organism like pneumocystis jirovecii among 
previously healthy homosexual men in United States. The term "acquired 
immunodeficiency syndrome," or AIDS was used first by public health officials in 
1982. In 1983, Dr. Luc Montagnier in Pasteur Institute, Paris isolated the virus from an 
patient with generalized lymphadenopathy and named it as lymphadenopathy-
associated virus (LAV)(19,20). Around the same time, Dr. Robert Gallo with his 
scientists in National Institute of health (NIH), Maryland isolated and named the virus 
as HTLV-III (human T-cell lymphotropic virus-type III), because it shared some 
features with HTLV I and HTLV II(21,22). Scientists under Dr. Jay Levy in University 
of California isolated the virus in 1984 and named it as AIDS associated Retroviruses 
(ARV)(23). In 1985, the name was changed to HIV (human immunodeficiency 
virus)(24). In 1986, the first case of AIDS in India was detected among commercial sex 
workers in Tamil Nadu(25). 
3.2. HIV 
3.2.1. Structure 
Human Immunodeficiency Virus belongs to the family Retroviridae and genus 
lentivirus. The mature HIV particle is spherical and measures around 100nm. It has an 
outer host-derived lipid envelope. The major envelope proteins are glycoproteins gp120 
and gp41 which forms the surface and transmembrane spikes respectively. It has a 
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cylindrical or conical inner core containing two identical copies of single stranded 
positive sense linear RNA. The core also contains enzymes that are required for 
functioning and replication of the virus – integrase, protease and reverse 
transcriptase(11,26,27). 
3.2.2. Genome 
The length of HIV-1 is 9.7kb. It has three structural genes that encode the structural 
proteins and six non-structural genes that encode various proteins that are involved in 
viral replication. The three main structural genes are the gag, pol and env genes. The 
gag gene encodes the core and matrix proteins – p24, p17, p6, p7. The pol gene encodes 
the enzymes – protease (p10), reverse transcriptase (p66/51) and integrase (p32). The 
env gene encodes the outer (gp120) and transmembrane (gp41) envelope proteins. The 
gag-pol-env genes are flanked by long terminal repeats which contain transcriptional 
regulatory proteins for gene expression. The non-structural genes are further divided 
into regulatory genes (tat, rev and nef) that encodes the regulatory proteins – 
transcriptional activator (p14), regulator protein (p19) and negative regulator protein 
(p27) respectively and the accessory genes (vif, vpr and vpu) that encodes the accessory 
proteins – viral infectivity factor (p23), viral protein R (p18) and viral protein U (p15-
16) (11,27).  
3.2.3. Molecular epidemiology 
The phylogenetic clustering of HIV-1 viral isolates globally into clades or subtypes is 
based on 20-50% differences in envelope nucleotide sequences(28). They are classified 
into three groups. The group M (Main/Major), N (New, Non-M, Non-O) and O 
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(Outlier)(29). The env proteins of group M and O show as much as 30-50% variation. 
Group N is phylogenetically equidistant from group M and O(29). Group M has 9 
different genetic subtypes A-D, F-H, J and K with E and I being circulating 
recombinants forms (CRFs)(28,30,31). The groups N and O are less frequent in human 
infections(32). Currently, 99.6% of all human infections globally is caused by group M 
of HIV-1 (32). The subtype C strains is prevalent in Africa, Latin America and 
Asia(28,31). India has a high prevalence of HIV-1 subtype C. The prevalence of subtype 
C varied in different parts of the country. In North India 78.4% and western India 96% 
of HIV-1 strains were subtype C(33,34). HIV-2 subtypes recognized in the world were 
A-H(35–37). When compared to HIV-1, HIV-2 strains were predominant in Africa. The 
HIV-2 strains identified in India till date are subtype A(38). The subtype A strain is the 
predominant in West African countries. Subtype A is estimated to cause 0.11% of all 
HIV infections in humans(32). 
3.3. Transmission 
HIV-1 is predominantly transmitted through sexual contact (both heterosexual and 
homosexual), by blood and blood products and from mother to child – intrapartum, 
perinatal and through breast milk. Transmission largely depends upon the viral load and 
the duration of exposure to that particular body fluid(10).  
The common route of HIV transmission worldwide is through sexual contact and 
accounts for 80% of adult HIV infection. Increased risk of HIV transmission is seen in 
homosexuals and individuals with multiple sexual partners. The risk of HIV spread is 
increased by 300 times when there is concomitant sexually transmitted infections (STI) 
caused by Herpes simplex-2, Hemophilus ducreyi, Treponema pallidum(11). 
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The probability of acquiring HIV from infected blood is about 90%(11). Transmission 
of HIV through blood has reduced to a large extent after intense screening in transfusion 
and transplant settings by HIV antibody testing and molecular detection. Intravenous 
drug users acquire HIV infection through this route. The prevalence of HIV infection 
in our country is 9.9% in intravenous drug users(6). The relative proportions of mother 
to child transmission of HIV are 23-30% before delivery, 50-60% during delivery and 
12-20% during breast feeding(11). 
In India, the HIV epidemic is concentrated in two groups of people through whom it is 
transmitted to healthy population – one group the high risk which includes male and 
female sex workers, transgender and intravenous drug abusers. The second group is 
bridge population which comprises a group of people who bridge the high risk groups 
with general population, mostly they are clients or partners of male and female sex 
workers include long distance truck drivers and migrants(39). 
3.4. Replication 
The primary targets of the HIV virus are the immune cells namely CD4+ T lymphocytes 
and macrophages. Replication starts with the attachment of the gp120 protein of virus 
to the CD4 receptors and co-receptors present on the surface of target cells which results 
in conformational changes in gp120. The chemokine receptors, CCR5 and CXCR4 
serves as the co-receptors for the macrophage trophic and non- macrophage trophic 
strains respectively. This results in exposure of the transmembrane envelope 
glycoprotein gp41 leading to fusion of the virion and target cells(40). Following fusion, 
matrix and capsid proteins in the virus are digested and releases viral RNA and enzymes 
into the cytoplasm of the cell. The viral genetic material gets incorporated into the cell 
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by endocytosis. The HIV enzyme reverse transcriptase uses the host nucleotides and 
converts the viral RNA into single-stranded DNA. During reverse transcription, random 
errors are made commonly due to the poor proofreading by reverse transcriptase. The 
double stranded DNA is synthesized from single stranded DNA by reverse 
transcriptase. The enzyme integrase integrates the double stranded DNA into the host 
DNA. Thus the virus replicates along with the DNA of the host cell. Following this, 
transcription occurs to produce viral mRNA which is translated into viral proteins in 
the cytoplasm. The final steps of HIV replication include assembly of the immature 
virion to the cell surface which leaves the host cell by budding. The mature virion that 
is released affects other immune cells thus continuing the process of replication(27,40).                                       
3.5. Pathogenesis 
The indicator of HIV disease is severe immunodeficiency due to progressive qualitative 
and quantitative deficiency of helper T cells by direct and indirect mechanisms(11). 
When the virus enters the body, there is massive multiplication of the virus in the target 
immune cells which results in CD4+ cell damage. Regardless of the host’s active 
immune response, the virus escapes the immunological clearance and releases the virion 
from the destructed cells which are concealed within the regional lymph nodes, this 
results in viremia. This occurs usually within 2-6 weeks when a threshold of replication 
is reached(41). Primary viremia sets in, which is characterized by non-specific 
symptoms that resembles any viral infection such as fever, fatigue, lymphadenopathy, 
rash, sore throat, weight loss and muscle pain. Once the infection is established, it 
persists lifelong(42,43). During the primary viremia phase, there is high plasma viral 
load and a transient fall in the CD4 count(41). In proportion to the viral replication, 
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there is profound immune activation by the T cells which results in release of various 
proinflammatory cytokines like TNF-α and interleukins. This state along with the direct 
viral effects leads to dramatic depletion, impaired production and dysfunction of the 
CD4 helper cells(44). The period and the duration of clinical latency after the primary 
infection depends upon the individual’s immune system. Once the CD4 count falls 
below 200 cells/μL, the infected individual is prone to get more opportunistic infections 
and progress to an advanced stage of HIV known as AIDS(41). The relationship 
between CD4 T lymphocyte count and viral load in an untreated HIV infected individual 
is depicted in Fig 1. 
Figure 1: Graph depicting relationship between CD4 T lymphocyte count and viral load 
in an untreated HIV infected individual. Adapted from Harrison’s Principles of Internal 
Medicine. Based on an original from Pantaleo et al (1993) 
  
13 
 
3.6. Immune Response 
After primary viremia, the HIV infected individuals normally mount a good immune 
response that usually curtails the level of viremia and may delay the development of the 
disease for 10 years. The immune response of the body to HIV infection includes 
humoral and cell mediated immunity. The immune response is against antigenic 
determinants of virion and also against viral proteins which is usually expressed on the 
surface of infected cells(11). 
3.6.1. Humoral immunity 
HIV specific antibodies appear normally within 3-6 weeks of primary infection and 
without fail within 12 weeks; exceptions include inability to produce HIV specific 
antibodies in certain individuals(11). The detection of these HIV specific antibodies is 
the foundation of most of the screening tests used for detection of HIV infection. 
The antibodies detected by ELISA and Western Blot are HIV binding antibodies and 
appear prior to the appearance of HIV neutralizing antibodies. 
The neutralizing antibodies usually appear after the initial decrease in plasma viral load 
and are more closely associated with the arrival of HIV -specific CD8+ T 
lymphocytes(11). The first antibodies which appear are against the immunodominant 
region of the envelope protein gp41. This is followed by antibodies to gag protein p24 
and the gag precursor p55(11). The antibodies to gp120 (envelope), p17 (gag) and p31 
and p66 (pol protein) appear after antibodies to p24. Envelope proteins gp120 and gp41 
are the only proteins which can elicit neutralizing antibodies. These neutralizing 
antibodies are considered as both protective and may also contribute to the pathogenesis 
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of HIV. The first neutralizing antibodies are against autologous infecting virus and 
usually appear after 12 weeks of infection. The virus is able escape the neutralizing 
antibodies because of the high rate of mutation. One important mechanism of immune 
escape is formation of glycan shield by linking of the glycosylation sites which 
interferes with envelope recognition(11).  
There are 5 main sites in the HIV envelope that elicits the production of neutralizing 
antibodies(11). They are 
i. CD4 binding site of gp120 
ii. Glycan dependent epitopes in V1/V2 region of gp120 
iii. Near the base of V3 region of gp120 
iv. gp120/gp41 bridge 
v. Membrane proximal region of gp41 
Some protective antibodies engage in antibody dependent cellular cytotoxicity (ADCC) 
where natural killer cells have Fc receptors and Fc portion of anti HIV antibodies bind 
to these Fc receptors. These armed natural killer cells bind to the cells which express 
HIV antigens and destroys them. The antibodies against the envelope proteins which 
participate in ADCC are highest early in infection(11). 
Avidity is the functional affinity and is the overall strength of the bonds between 
antibodies and their corresponding antigens. In HIV-1 infection, avidity increases over 
time following seroconversion. Maturation in antibodies against gp41 reflects the time 
since seroconversion and remains high in individuals with long term infection and in 
AIDS. But the same cannot be said of anti-p24 and anti-p17. Before the onset of AIDS, 
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the avidity of antibodies against p24 falls. The avidity of antibodies against gp41 is of 
value in identifying cases of recent HIV infection but not the avidity of antibodies 
against p24 or p17 (45). In early stages of primary immune response usually low avidity 
antibodies are produced. The hyper mutation in V region and the preferential selection 
of the high affinity B cells by antigen leads to the increase in the overall avidity over 
period of months. As this response matures usually when maximum antibody titers have 
been reached. The maturation of the antibody response is useful in serodiagnosis of viral 
infections for the timing of infection. Antibody maturation occurs in the presence of 
active viral replication(46). Using paired sera from cases of primary infection with a 
known date of onset of illness or seroconversion, an avidity maturation time course has 
been determined. Such avidity studies are now used in risk assessment in cases of 
rubella during pregnancy where it can confirm recent infections in the face of equivocal 
IgM results and for some time after maximum IgG antibody titers have been 
reached(45,47–49).  
3.6.2. Cellular Immunity   
T cell immunity can be mediated by inducer CD4+ T helper cells and immunoregulatory 
CD 8+ killer T cells. CD4+ T helper cells specific for HIV can be detected using flow 
cytometry to measure intracellular cytokine production or through lymphocyte 
proliferation assay using HIV antigen p24. These cells help HIV specific B cells and 
CD 8+ T cytotoxic cells in mounting an immune response. CD 4+ T cells may also 
directly kill HIV infected cells. During generation of an immune response to HIV, the 
CD4+ T cells may be the preferred targets of HIV infection by infected antigen 
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presenting cells. When there is high viral load, CD4+ T cells responds to HIV antigens 
by shifting from proliferation and IL-2 production to IFN-γ production(11). 
HIV specific CD8+ T cells which are MHC class 1 restricted have been detected in the 
peripheral blood samples of HIV-1 infected individuals. These cells include cytotoxic 
T cells that produce perforins and T cells which can express an array of cytokines such 
as IFN-γ, IL-2, MIP- 1β and TNF α. Cytotoxic T lymphocytes (CTL) have been 
detected within weeks of HIV infection and before the appearance of virus in blood. 
They exert a selective pressure on the evolution of the population of circulating viruses. 
CD8+ T lymphocytes through their HIV specific antigen receptor bind to the target cells 
and results in the lytic destruction of target cells having autologous MHC class 1 
molecules presenting HIV antigens. Two types of cytotoxic T lymphocyte activity are 
seen in HIV infected individuals. The first type is known as spontaneous CTL activity 
where the cytotoxic T lymphocytes directly lyses appropriate target cells in culture 
without prior in vitro stimulation. The second type of CTL activity indicates the 
precursor frequency of CTLs (CTLp); this CTL activity can be demonstrated by 
stimulation of CD8+ T cells in vitro using a mitogen such as phytohemagglutinin or 
anti-CD3 antibody(11). 
The ability of CD8+ T lymphocytes from an HIV infected individual to inhibit the 
replication of HIV in tissue culture without killing infected targets is known as non 
cytolytic CD8+ T cell mediated suppression of HIV replication (11,43,50). 
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3.7. Classification of HIV infection 
Two major systems of classification are used widely for HIV infection. The WHO 
classification system has clinical staging and is used widely in low resource setting 
where CD4 counts may not be available. The CDC staging system combines both CD4 
counts and clinical staging together(51). 
Table 1: WHO classification of HIV 
Staging  Clinical Presentation  
Primary HIV 
infection 
Asymptomatic  
Acute retroviral syndrome  
Stage 1 Asymptomatic  
Persistent generalized lymphadenopathy  
Stage 2 Moderate unexplained weight loss (<10%)  
Recurrent respiratory tract infections  
Angular cheilitis  
Herpes zoster  
Recurrent oral ulcerations  
Seborrheic dermatitis  
Papular pruritic eruptions  
Fungal nail infections of fingers 
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Stage 3 
Unexplained severe weight loss (>10%)  
Unexplained persistent fever for >1 month 
Unexplained chronic diarrhea for >1 month  
Persistent oral candidiasis  
Oral hairy leukoplakia  
Pulmonary tuberculosis  
Severe presumed bacterial infections (Pneumonia, meningitis, 
bacteremia, bone or joint infection)  
Acute necrotizing ulcerative gingivitis, stomatitis or periodontitis  
Anemia or Neutropenia or Chronic thrombocytopenia 
 
 
 
 
 
 
Stage 4 
Conditions where a presumptive diagnosis can be made on the 
basis of clinical signs or simple investigations  
HIV wasting syndrome  
Pneumocystis pneumonia  
Recurrent severe bacterial pneumonia  
Chronic herpes simplex infection (>1 month or visceral herpes at any site)  
Esophageal candidiasis   
Extra pulmonary tuberculosis  
Cytomegalovirus infection (infection of retina or other organs)  
Kaposi sarcoma  
Toxoplasmosis of the central nervous tissue 
HIV encephalopathy  
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Conditions where confirmatory diagnostic testing is necessary:  
 
Extra pulmonary Cryptococcosis including meningitis  
Progressive multifocal leukoencephalopathy 
Disseminated non tuberculosis mycobacteria infection  
Disseminated mycosis 
Candida of the bronchi, trachea, or lungs  
Recurrent non typhoidal Salmonella bacteremia   
Chronic cryptosporidiosis or isosporiasis (with diarrhea)  
Invasive cervical carcinoma 
Atypical disseminated leishmaniasis  
Lymphoma  
Symptomatic HIV-associated cardiomyopathy or nephropathy 
Reactivation of American trypanosomiasis  
 
Table 2: CDC classification of HIV  
CD 4 cell count Clinical Category 
Category A Category B Category C 
≥ 500 cells/μL Asymptomatic, acute 
HIV or Persistent 
generalized 
lymphadenopathy 
(A1, A2, A3) 
Symptomatic 
conditions except A 
and C 
(B1, B2, B3) 
AIDS defining 
illnesses 
(C1, C2, C3) 
 
200 – 499 cells/μL 
< 200 cells/μL 
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3.8. HIV Testing Strategies 
National AIDS Control Organisation (NACO) is a section of the Ministry of Health and 
Family Welfare (MOHFW) responsible for formulating policies and executing 
programmes for the prevention and control of the HIV in India. National AIDS control 
programme (NACP) was first established in 1992, which aimed at controlling the spread 
of HIV infection. NACP-IV (2012-2017) is the current programme. and it aims to 
reduce annual incidence of HIV infections by 50% (5,52). 
Safety of blood and blood products is of prime importance because of the huge risk 
involved in the transmission of HIV through blood and blood products. The positive 
predictive value is low in populations with low HIV prevalence so the 
WHO/Government of India evolved strategies. There are three different strategies to 
detect HIV infection in the different population groups and different situations. The 
various strategies designated involve the use of categories of tests in many permutations 
and combinations(53). 
1. ELISA or Rapid tests are used in strategy I, II, & III 
2. Confirmatory tests with high specificity like western blot and line 
immunoassays, are used in cases of indeterminate/discordant result of ELISA or 
Rapid tests 
Recommendation by NACO for HIV testing 
ELISA kits with a sensitivity of ≥99.5% and a specificity of ≥98%.  
Rapid kits with a sensitivity and specificity ≥99.5% and ≥98% respectively. 
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The different strategies for HIV testing used in different situations are shown in Fig 2, 
3, 4 and 5 
 
 
 
Figure 2: Strategy 1 – For blood transfusion/transplant safety 
Figure 3: Strategy 2A is used for sentinel surveillance 
  
22 
 
 
 
Figure4: Strategy 2 B – Used for diagnosis in symptomatic individuals 
Figure 5: Strategy 3 - Used for diagnosis in asymptomatic individuals 
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The assays A1, A2, A3 are 3 different assays which are based on different principles or 
different antigenic compositions. A1 should be of high sensitivity. A2 and A3 should be 
of high specificity to minimize false positive reactions. A2 and A3 should also be able 
to differentiate between HIV 1 & 2 infections. In case of indeterminate, testing should 
be repeated on a second specimen taken after 14-28 days. If results continue to be 
indeterminate, then the specimen is to be subjected to Western Blot /PCR(53). 
3.9. Recent infection  
There are many developed laboratory tests which differentiates recently acquired HIV 
infections from long term infection based on the principle that the immunological 
response to HIV infection takes a few months to evolve after infection. The indicator of 
recent infection is usually a marker which is present during the initial period but later 
disappears. In such tests, “recent” usually means the duration of up to one year after an 
individual has acquired the infection (14). 
HIV incidence is the rate at which a population acquires HIV infection. It is a 
quantitative indicator that measures the magnitude of current HIV transmission in a 
community. 
Estimation the HIV incidence is done for population surveillance, for evaluating of the 
impact of preventive interventions and for evaluating the efficacy of early treatment or 
a new preventive intervention. Surveillance helps in identifying the incidence patterns 
between different population groups and over time. Surveillance may monitor HIV 
infection in the general population or in the high risk groups and advices governments 
regarding resource allocation. 
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Incidence ratios evaluates the outcome of an intervention by comparing the incidence 
between two populations or across two time periods. Only after approximating the 
absolute incidence with some accuracy are populations selected for early treatment or 
prevention cohort. The feasibility of population selection depends on detecting a 
specific number of new HIV infections in the population. 
Estimation using laboratory tests for recent HIV infection includes estimating the 
number of individuals with newly acquired HIV-1 infection in a population using a test 
for recent HIV infection and using a mathematical formula to derive HIV incidence. 
It does not require repeated test in individuals so can be used in samples collected in 
cross sectional studies. Its disadvantages are biases that arise in sample selection and 
chance of misclassifying long term infection as recent infection (false recent rate – 
FRR). Another limitation is the difference in assay performance across different 
population groups and different HIV subtypes. The incidence derived from multiple 
methods is more reliable than when it is based on a single method (12). 
3.9.1. Tests available for recent infections 
Majority of the Tests for Recent (HIV) Infections (TRI) are based on principle that 
maturation and evolution of HIV-1 specific antibodies occur within first two years of 
seroconversion(15). 
Till date, there are 8 types of assays as tests for recent HIV infection. Among these 
assays , some have been specifically developed for identifying recent infection, while 
others are modifications of commercial HIV diagnostic tests(54–56).  
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1. Less-sensitive enzyme immunoassay – Majority of the antibody assays for HIV 
infection can be modified for use as a test for recent infection utilizing the 
principle that antibody titers rise for few months after acquisition of the infection 
Majority of the standard antibody assays for HIV infection can be altered for use 
as a test for recent infection utilizing the principle that antibody titers rise for 
several months after acquiring the infection. Janssen et al described this method 
first. It is based on the enzyme immunoassay (EIA) produced by Abbott 
laboratories and which was modified to create a less-sensitive HIV antibody 
test(57). The enzyme immunoassay was made less sensitive by diluting the 
plasma and reducing the incubation time. Confirmed HIV-1 positive samples 
were tested again using the less sensitive EIA. Individuals with recent HIV 
infection and an early immune response had lower level of HIV antibodies and 
therefore they tested negative in the less-sensitive EIA. 
Many other assays have also been modified in a similar manner way to estimate 
incidence. Two immunoassays which have been commercially modified as less-
sensitive EIAs were the Avioq HIV-1 Microelisa and Abbott 3A11. For detection 
of recent HIV infection even rapid antibody tests have been modified. The 
limitation of these assays were that they used HIV-1 subtype B alone as antigen 
so it could not be used in other parts of the world where there is prevalence of 
other subtypes of HIV (12) 
2. Proportional assay – This assay measures the proportion of all the 
immunoglobulin G in an individual’s serum which is specifically against HIV. 
The principle is that the proportion IgG is lower in recent infection than in long 
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term infection. The commercial assay based on this principle is the IgG antibody 
capture BED-enzyme immunoassay (BED-CEIA). BED CEIA was developed 
particularly for the identification of recent HIV infection(58). BED capture EIA 
uses a synthetic antigen and this assay can be used against HIV subtypes B, E 
and D (12). 
3. Avidity assay – Avidity is the strength of the bond between an antigen and an 
antibody. These assays are based on the principle that individuals with recent 
have antibodies of low avidity. After measuring the total anti-HIV response, a 
denaturation agent is added which separates the antibodies with weak bonds. 
Then avidity index is calculated as optical density (OD) of the well treated with 
denaturation agent divided by OD of well washed with phosphate buffered 
saline. Avidity index of ≤ 0.80 is considered as recent infection and avidity index 
> 0.80 is considered as long term infection(59,60). 
4. p24 antigen – It is possible to detect p24 antigen within a few days after the 
presence of virus in the blood and before HIV antibodies can be detected. When 
the body initiates an immune response to the infection the level of p24 antigen 
falls. The presence of p24 antigen in absence of HIV specific antibodies is 
suggestive of recent infection. The use of this test is limited for detecting recent 
infection as the presence p24 antigen is brief (1-2 weeks) and unreliable (12).  
5. IDE-V3 assay – The basis of this assay is the two conserved sequences in the 
envelope protein of HIV-1. They are  
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 Immunodominant epitope (i.e. IDE) of envelope protein gp41 comprising 
of two oligopeptides of 30 amino acids; and one of the oligopeptide is 
from group M and the other oligopeptide is from HIV-1 subtype D 
 Conserved sequence from the V3 loop of glycoprotein120. It contains 
oligopeptides from HIV-1 subtypes A, B, C, D and E. 
The assay uses a formula to calculate the combination of quantitative 
responses to the antigens from each region to differentiate recent infection 
from long term infection. The IDE-V3 assay has low sensitivity (12,61). 
6. HIV RNA – The HIV RNA detection in the absence of HIV antibody is also 
utilized to identify recent HIV infection. Compared to p24 antigen, HIV RNA 
can be detected much earlier (62). If pooled HIV RNA is used, it can increase 
the accuracy of RNA amplification assay and lower the cost of testing. The 
limitation is, it requires very large sample population size for determining HIV 
incidence. 
7. IgG3 anti-p24 – During the course of an infection, the IgG isotypes formed in 
response to the infection varies. Isotype IgG3 is present transiently during the 
initial few months of HIV-1 infection. IgG3 response is most reliable against p24 
antigen. An enzyme immunoassay was developed where IgG3 to p24 antigen 
was typically detectable only during the first four months of infection. The 
results from the initial studies of this assay have not been generalized to different 
groups with different subtypes of HIV infection (12).  
8. Line immunoassay – It is an immunoblot that utilizes limited range of 
recombinant antigens and oligopeptides from HIV-1 and HIV-2. In routine 
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diagnostics it confirms the presence of HIV specific antibodies. Inno-Line 
immunoassay HIV 1/2 score is utilized to interpret results as either long term 
infection or recent infection (63). It is an expensive assay. 
9. HIV-1 LAg-Avidity EIA 
It is a quantitative limiting antigen (LAg) avidity enzyme immunoassay (EIA) 
for differentiating between long term and recent HIV-1 infections. Individuals 
with recent HIV-1 infections normally have HIV IgG with lower avidity than 
those with established HIV-1 infections. It measures avidity of the HIV-1 
antibodies in both serum and plasma samples(16,64). 
The earliest tests were desensitized or “less sensitive” commercially available 
HIV immunoassays (57,65–71) based on the principle that lower titers of HIV 
antibodies were typical of recent infections. All the less sensitive commercial 
immunoassays were a modification of HIV immunoassay that used HIV-1 
subtype B as antigen so the assay was unreliable in populations in other parts of 
world (70,71). The subtype bias was overcome by the utilization of synthetic 
antigen which had sequences from different subtypes and a capture format 
helped to measure the proportion of HIV-1 antibodies which increased after 
seroconversion. The BED capture enzyme immunoassay utilizes a synthetic 
antigen with sequences from HIV-1 subtype B, E and D (58). But BED CEIA 
used in several studies (72–77) showed a high false recency rates which gave an 
overestimation of HIV-1 incidence being reported (78–81) and consequently 
adjustments were proposed to improve the accuracy of the incidence estimates 
after the test(82,83). HIV incidence utilizing the assays based on antibody avidity 
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have shown low false recency rates in studies in US populations (84,85). In order 
to overcome the biases of the previous assays, the wells were coated with a 
recombinant protein (rIDR-M) that had divergent sequences from 
immunodominant region of gp41 from all the major subtypes and recombinants 
of HIV-1 group M. Also limiting the concentration of the antigen in the wells 
detected only antibodies with high avidity. Studies done in Africa using this 
assay showed a false recency rate of less than 1%(86). As this assay is based on 
the binding strength of the antibodies or functional avidity, it is less likely to be 
affected by disease state compared to previous assays. Normalized optical 
density (ODn) cutoff of this assay is 1.5 to classify recent and long-term 
infections. In LAg avidity assay, ODn value = 1.5 denotes a mean duration of 
recent infection (MDRI) of 130 days (95% CI, 118-142)(87). The limitations of 
this assay is that the usefulness of this assay at individual level has not yet be 
assessed particularly when ODn values are close to the cutoff. 
10. Limiting-Antigen Avidity Dot Immuno-Gold Filtration Assay 
It is a rapid membrane based immunodiagnostic technique. Compared to the 
enzyme immunoassay, they are more suitable for onsite testing because it is 
rapid, economical and convenient and has visual characteristics. This is based on 
avidity of antibody between long-term and recent infection. This assay increases 
the sensitivity and accuracy by adding a silver staining technique.  Its agreement 
with LAg avidity assay was 95.36% (κ = 0.75) and 92.10% with BED assay (κ 
= 0.65)(88).  
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3.10. Avidity and Antiretroviral therapy 
HIV-1 infected individuals who were administered antiretroviral therapy (ART) 
showed impaired production and maturation of IgG compared to before administration 
of ART. ART seems to prevent the appearance of IgG antibodies(46). It can be due to 
suppression of viral replication by ART as HIV replication results in production of 
antibodies directly because of stimulating antigens or indirectly, due to release of 
cytokines like Interleukin-6 and interferon which stimulate the B lymphocytes. Western 
blot analysis has shown only limited number of recently HIV-1 infected individuals 
showing high reactivity to pol and gag proteins. Administration of ART prevents 
increase in avidity index and discontinuation of ART results increase in avidity 
index(17). ART in primary HIV infection partially prevents the emergence of HIV-1 
IgG antibodies(89). Viral suppression naturally induced and due to ART have 
misclassified as recent infection those who have had long term HIV-1 infection when 
tested using the BED capture EIA. Also viral breakthrough that is when an individual 
on ART has an emergence of viral load >1000 copies/ml, such individuals showed an 
increased proportion of IgG measured using BED capture EIA(18).  
3.11. HIV Drug resistance 
In 2004, WHO and CDC, along with HIVResNet, developed a global strategy for the 
assessment and prevention of HIV drug resistance. And one of the components of the 
strategy was to check for transmitted drug resistance in recently infected HIV-1 
individuals(90,91). 
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HIV drug resistance is of two type – transmitted drug resistance and acquired resistance 
associated with treatment failure. 
Primary or Transmitted drug resistance 
Transmitted drug resistance is defined as an occurring when individuals are newly 
infected with an already resistant virus(92,93). The increased use of antiretroviral drugs 
has resulted in an increase in the incidence of drug resistance and eventually a large 
pool of resistant virus strains becoming available to establish new infections.  The 
transmission of drug resistant viruses does not depend on a particular route of  infection 
(94).  
Acquired Resistance occurs when HIV-1 infected individual on ART and was 
responding initially but later develops resistance to the antiretroviral drugs. That is, they 
acquired resistance following administration of ART.  
Drug resistant HIV-1 can interfere with successful treatment and management of 
therapy in HIV-1 infected individuals.  So when an individual has drug resistance, the 
treatment options available is limited and it affects our efforts to slow down the 
progression of the disease. Furthermore, this can lead to increased rates of transmitted 
drug resistance because of the pool of drug resistant strains available to infect more 
people (94). 
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4. Materials and Methods 
The study was done in the Departments of Clinical Virology and Infectious Diseases, 
Christian Medical College and Hospital, Vellore. It was approved by the Institutional 
Review Board (Reference IRB Minutes No: 9527 dated 07.07.2015). 
4.1. Materials 
Study subjects: 
The study participants were classified in 5 different groups  
Group 1: Consecutive positive samples (using NACO strategy 3) of HIV-1 infected 
individuals from ICTC, CMCH. The study was explained to all the participating 
individuals and was recruited in the study only after getting a written informed consent. 
This cross sectional study was done during a period of 1 year (August 2015 – July 2016). 
Inclusion criteria for samples from ICTC:  
1. Adults >18yrs of age  
2. HIV-1 infected individuals  
3. Treatment naive  
4. Individuals willing participate in the study by signing informed consent 
Group 2: First negative sample from ICTC volunteers of each week who are negative 
for HIV infection to serve as controls.  
Inclusion criteria for control from ICTC:  
1. Adults >18yrs of age  
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2. Negative for HIV infection 
3. Individuals willing participate in the study by signing informed consent 
 
Archived samples – Paired sera  
Group 3: Archived paired sera of HIV-1 infected individual prior to treatment and after 
6 months to 1 year of treatment and showing response to treatment. 
Inclusion criteria for archived samples  
1. Adults >18yrs of age  
2. HIV-1 infected individuals  
3. Sufficient volume of sample- treatment naïve and following 6 to 12 months’ 
treatment with CD4 counts and HIV-1 viral loads available  
4. Individuals who have given informed consent for additional studies and wavier 
towards this study 
Group 4: Archived paired sera of HIV-1 infected individual on ART for a minimum of 
one year, showing response to treatment and after developing drug resistance  
Inclusion criteria for archived samples:  
1. Adults >18yrs of age  
2. HIV- 1 infected individuals on treatment for at least 1 year initially showing response 
to treatment and later showing treatment failure with CD4 counts and HIV-1 viral loads 
available  
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4. Individuals who have given informed consent for additional studies and wavier 
towards this study 
Group 5: Archived samples (n = 3) positive by 4th generation assays were also used 
These samples were tested using multiple 3rd and 4th generation assays, those samples 
which tested positive by 4th generation assays and negative by 3rd generation assays 
were assumed to be negative for IgG antibody and positive for HIV-1 antigen. All these 
were characterized samples positive only for antigen and negative for antibody. Hence 
we assumed that the sample will be negative for the avidity assay. So it was used to 
check the specificity of the assay. 
Exclusion criteria for all groups  
1. Individuals who haven’t given consent for additional studies  
2. Individuals < 18years of age  
3. Pregnant women  
4. HIV-2 infected individuals 
5.1.1. Sample size:  
Group 1 and 2 
In our ICTC, 15-20 positives cases of HIV-1 come every month. Of these, based on 
history, 40-50% are recently infected. Based on this data, taking a prevalence (p) of 
45% recently infected individuals among HIV-1 infected individuals with precision (d) 
of 10. 
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Here p (prevalence) = 45%, q (100-p) =55%  
A precision (d) of 10, with 95% confidence interval (alpha error (Zα) of 1.96)  
𝑆𝑎𝑚𝑝𝑙𝑒 𝑠𝑖𝑧𝑒 (𝑛) =𝑍2×𝑝× (100−𝑝) ÷𝑑2  
Sample size (n) = (1.96 x 1.96) x 45x 55/ 100 ≈ 96 
Even though the calculated sample size was 96, blood samples were collected from 117 
consecutive treatment naïve HIV-1 infected individuals who attended the ICTC, 
CMCH. The samples were collected from those who gave consent for the study. 
For controls (Group 2), we collected the first sample of the week which tested negative 
for HIV in ICTC with written informed consent from the volunteer (n = 40) 
For the group 3 the sample size was calculated in the following way, 
Study by Re et al showed decrease in the avidity antibodies in approximately 80% of 
HIV-1 infected individuals(17).  
With a precision d=15%. Prevalence (p1) = 82%, q1= (100-p) =18  
𝑆𝑎𝑚𝑝𝑙𝑒 𝑠𝑖𝑧𝑒=𝑍2 ×𝑝× (100−𝑝) ÷𝑑2  
Sample size = 1.96x 1.96 x 82x 18/225 ≈ 26  
In group 4 all the available pairs were taken (n=7) 
Information collected from the study recruits included the individuals’ age, sex, 
regional identification, marital status, occupation, history of exposure and any high risk 
behavior. 
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Samples tested 
1. Serum samples from treatment naïve HIV-1 infected individuals (n = 117) 
2. Serum samples from HIV negative individuals (n = 40) 
3. Archived paired sera of HIV-1 infected individual prior to treatment and after 6 
months to 1 year of treatment and showing response to treatment (n = 25 x 2 = 
50) 
4. Archived paired sera of HIV-1 infected individual on ART for 1year, showing 
response to treatment and after developing drug resistance (n = 7 x 2 = 14) 
5. HIV-1 infected individuals who tested positive by 4th generation assays and 
negative by 3rd generation assays (n = 3) 
Specimen 
A total of 2ml of blood sample was collected in a sterile red capped BD vacutainer (New 
Jersey, USA) in ICTC. After testing was done in ICTC, the remaining sample was 
obtained for the study with written informed consent. Serum was separated and stored 
in multiple aliquots of 200 μL at -60°C until testing.  
For group 3, 4 and 5 the specimens were aliquots of plasma/ serum sample stored at      
 -60°C / -30°C until it was tested. 
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5.2. Methods 
5.2.1. HIV-1 limiting antigen avidity assay 
The LAg Avidity enzyme immunoassay (Sedia Biosciences Corporation, Oregon, 
USA) is a commercially available single well assay based on avidity of the antibody. 
Study algorithm 
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The wells of this assay are coated with recombinant proteins containing the HIV-1 
immune dominant region (IDR) of gp41. 
1. The assay had four types of controls - the negative control, the calibrator, the low 
positive control and the high positive control. All the controls were tested in 
triplicates as per manufacturer’s instruction and during the initial testing all 
specimens were tested singly.  
2. Serum specimens was diluted 1:101 that is 500 μL of sample diluent and 5 μL of 
sample. The sample diluent contains phosphate buffered saline, blocking agents, 
detergent and preservatives. The Eppendorf tubes were marked with the sample 
ID and 500 μL sample diluent was added in each tube and 5 μL of each control, 
calibrator, and sample was transferred to respective Eppendorf tubes. 
3. After mixing properly, 100 μL of diluted negative control was added to wells 
A1, B1 and C1 of the avidity plate; 100 μL of diluted calibrators was added to 
the wells D1, E1 and F1; 100 μL of diluted low positive controls was added to 
wells G1, H1 and A2 and 100 μL of diluted high positive control was added to 
wells B2, C2 and D2. After addition of controls, the samples were added in the 
respective wells. The plate was sealed and incubated for 1 hour at 37°C (±2°C).  
4. After 1 hour, the avidity plate was washed 4 times with 1X wash buffer. To each 
well, 300 μL of wash buffer was added and allowed to soak for 10 seconds. After 
washing, residual buffer was removed by gently tapping the plate upside down 
on absorbent paper.  
5. Then 200μL of dissociation buffer was added to each well. Plate was sealed and 
incubated for exactly 15 minutes at 37°C (±2°C).  
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6. During this time conjugate working solution was prepared, 12 ml of sample 
diluent was transferred to sterile clean petri dish and 12 μL of the goat anti-
human IgG conjugated to horse radish peroxidase (HRP) concentrate was added 
to it and to prepare a 1:1001 dilution. The petri dish was closed and contents 
were mixed gently.  
7. After the incubation, the plate was washed with 4 times with 1X wash buffer and 
residual buffer was removed by gently tapping the plate on an absorbent paper. 
8. After this, 100 μL of the conjugate working solution was added to each well. The 
plate was sealed and incubated at 37°C (±2°C) for 30 minutes.  
9. After the incubation period, the plate was washed 4 times with 1X wash buffer 
and residual buffer removed by gently tapping the plate on an absorbent paper 
10. Then 100 μL of tetramethyl benzidine (TMB) substrate was added to each well. 
The plate was incubated for exactly 15 minutes at 25°C (±2° C) avoiding 
exposure to light.  
11. After 15 minutes of TMB incubation, the reaction was stopped by addition of 
100μL of stop solution (dilute acid) to each well.  
12. The plate was read at 450 nm and 620-650 nm using a spectrophotometer 
(μQuant™, BioTek Instruments Inc. Vermont, USA) immediately after the 
addition of stop solution 
13. Run validation and results were calculated according to the manufacturer’s 
instruction. The median OD values of controls and calibrator must be within the 
ranges for the test to be valid. Table 3. 
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Table 3: Acceptable OD ranges for Controls and Calibrator in LAg avidity assay 
used in the study 
 Negative 
control 
Calibrator Low positive 
control 
High positive 
control 
Minimum OD 0.000 0.400 0.190 0.830 
Maximum OD 0.175 0.950 0.520 1.820 
 
The normalized OD (ODn) was calculated for each control, calibrator and 
sample. Normalization of the OD value using an internal calibrator decreases the 
assay variability and increases the reproducibility(16,83). For the test to be valid 
the ODn of controls and calibrators must within range. 
 
      ODn value of control and calibrator must fall within the acceptable range. Table 4. 
Table 4: Acceptable ODn ranges for the Controls and Calibrator in LAg avidity 
assay used in the study 
 Negative 
control 
Calibrator Low positive 
control 
High positive 
control 
Minimum ODn 0.000 1.000 0.370 1.500 
Maximum ODn 0.240 1.000 0.700 2.400 
  
14. During screening mode, if ODn was > 2.0, then long term infection and if ODn 
≤ 2.0, then confirmatory testing was done. 
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15. During confirmatory testing, if the ODn was ≤1.5 then recent infection. If ODn 
was > 1.5, then long term infection. Confirmatory testing of the samples was 
done in triplicates. That is the controls, calibrators were tested as for the 
screening test but the difference is that all samples with ODn ≤ 2.0 were tested 
in triplicates. When samples are run in triplicate the mean OD is used to calculate 
the ODn. The algorithm and interpretation for LAg avidity assay is shown in Fig 
6. 
 
16. The avidity of the antibody was measured as normalized optical density value 
adjusted by calibrator and controls. Samples with ODn value below 1.5 was 
classified as ‘recent’ and the mean duration of recency (MDR) was 130 days.  
 
 
Figure 6: Algorithm for testing and interpretation of ODn values obtained in LAg 
avidity EIA 
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5.2.2. In house avidity assay 
The in house avidity assay was a modification of Microlisa HIV ELISA (Second 
generation ELISA using HIV envelope proteins gp41, gp120 for HIV-1 and gp36 for 
HIV-2) from J. Mitra (New Delhi, India) diagnostic products. The manufacturer’s 
instruction was followed for addition of controls and sample to micro wells. The 
treatment of the duplicate wells with 7M urea solution (pH=3.0) is the modification 
used. 
 Preparation of 7M urea solution 
o Urea was obtained from Fisher Scientific, Product No: 20885 
o The molecular weight of urea = 60.06 g/mol 
o 1M Urea solution = 1mole in 1L of distilled water (DW) = 60.06g in 1000ml 
of DW 
o 7M Urea solution = 7 x 60.06 g in 1000ml DW= 420.42 g in 1000 ml of DW 
o For preparation of 100 ml of urea solution 42.04 g of urea was added in 100ml 
of DW 
o The initial pH of the prepared solution was 6.4 and it set to 3.4 using pH 
meter CyberScan pH 1500 (Thermo Scientific).  
o The prepared urea solution was filtered and then stored at 4°C until use 
Procedure 
1. The controls were ready to use and required no dilution. 100μL of sample diluent 
was added to first well as blank, and 100μL of negative control was added in 
triplicate and positive controls were added 4 times as shown in Table 5. 
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Table 5: The plate configuration used for the in-house avidity assay  
Washed with Wash Buffer Treated with Urea solution  
BL 1 9 17 25 33 1 9 17 25 33  
NC 2 10 18 26 34 2 10 18 26 34  
NC 3 11 19 27 35 3 11 19 27 35  
NC 4 12 20 28 36 4 12 20 28 36  
PC 5 13 21 29 37 5 13 21 29 37  
PC 6 14 22 30 38 6 14 22 30 38  
PC 7 15 23 31 39 7 15 23 31 39  
PC 8 16 24 32 40 8 16 24 32 40  
 
 
 
2. The sample was diluted in sample diluent 1:11, that is 10μL of sample and 100μL 
of sample diluent. For a sample which was tested, 10 μL each was added in two 
different wells, that is, one well which was washed with wash buffer and second 
well which was washed with 7M urea solution as shown in Table 5. It was 
incubated at 37°C for 30 minutes.  
3. After incubation, the entire plate was washed once with wash buffer (Phosphate 
buffered saline, included in the kit) using an automated strip washer (ELx50 strip 
washer, Bio-Tek Inc. USA). After wash, residual buffer was removed by gently 
tapping the plate over an absorbent paper.  
4. Subsequently 300μL of wash buffer was added to the wells which had the 
controls and the samples. To the duplicate wells, 300μL of 7M urea solution with 
pH=3.0 was added and the plate was incubated for 15 minutes at room 
temperature. Urea solution was used as a dissociation agent and it has effective 
separation at pH=3.0(16). 
*BL= Blank, NC = Negative control, PC = Positive control, the samples and their 
corresponding duplicates are depicting with the same number, the numbers in black depict 
the wells treated with wash buffer and the numbers in red depict the wells treated with 7M 
urea solution respective duplicate  
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5. After incubation, the plate was washed 5 times with wash buffer.  
6. The concentrate of anti-human IgG conjugated with horse radish peroxidase was 
diluted with conjugate diluent in the ratio 1:100 and 100 μL of working conjugate 
was added to each well and the plate was incubated at 37°C for 30 minutes.  
7. After incubation, the plate was washed 5 times with wash buffer. 
8. Tetramethylbenzidine (TMB) substrate was diluted in TMB diluent in the ratio 
1:1 and 100μL of working substrate was added to all the wells and plate was 
incubated at room temperature for 30 minutes avoiding exposure to light 
9. After 30 minutes, the reaction was stopped using the stop solution (1N sulfuric 
acid).  
10. The plate was read at 450nm using a spectrophotometer (μQuant™, BioTek 
Instruments Inc. Vermont, USA) after blanking the blank well within 30 minutes 
of adding the stop solution. 
Test was valid when the controls were within limits as shown in Table 6. 
Table 6: Acceptable limit for controls in house assay based on manufacturer’s 
instruction for the commercial assay   
 Blank Negative Control Positive Control 
OD value < 0.100 ≤ 0.150 ≥ 0.50 
 
The Avidity Index (AI) is calculated by formula as previously described(45) 
To be considered as recently infected the AI value cutoff was ≤ 0.80(60,59) and all 
samples above > 0.80 were considered as long term infection. 
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When the AI values were ≤ 0.80, the samples were tested in duplicates. In cases where 
there was discrepancy with AI and ODn. The samples were also tested in duplicates. 
And the median value was considered as the avidity index. 
5.2.3. Western Blot 
The assay used for the Western Blot was HIV BLOT 2.2 (MP Diagnostics, Singapore). 
It is a qualitative EIA for the detection of antibodies to HIV-1 and HIV-2 in human 
serum or plasma. It is a supplementary test used for specimens found repeatedly reactive 
using screening procedures like ELISA. 
The nitrocellulose strips were blotted with separated antigenic proteins from inactivated 
HIV-1 by electrophoretic blotting procedures, combined with a specific HIV-2 
synthetic protein on the same strip. Each strip was included with an internal sample 
control to reduce the risk of false negatives due to technical errors and to ensure that the 
sample has been added. The serum samples to be tested were inactivated at 56°C in 
water bath for 30 minutes. 
Procedure 
1. The individual nitrocellulose strips were removed from the tube and placed in 
trough with the numbered side of strip facing up 
2. To each trough, 2ml of wash buffer (tris buffer with tween 20) was added and 
incubated at room temperature on a rocking platform for 2 minutes.  
3. The buffer was removed by aspiration. 
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4.  After aspiration, 2ml of blotting buffer (tris buffer with inactivated goat serum 
and non-fat milk powder) was added to each trough to prevent nonspecific 
binding of the proteins 
5. Then 20μL of controls and sample were added to the respective trough. The tray 
was covered and incubated at room temperature on rocking platform and 
incubated overnight. The specific antibodies to HIV-1 if present will bind to the 
different antigenic proteins.  
6. After an overnight incubation (16-20 hours), the tray was carefully uncovered to 
avoid mixing or splashing of samples. The contents of the tray were aspirated 
and the aspirator tips were changed between samples to avoid cross 
contamination. 
7. The troughs were washed 3 times with wash buffer. The strips were allowed to 
soak for 5 minutes in the wash buffer between the washes (on the rocking 
platform) 
8. After washing step, 2ml of working conjugate solution (goat anti human IgG 
conjugated with alkaline phosphatase and blotting buffer – 1:1000) was added to 
each trough and incubated for 30 minutes. 
9. The conjugate was aspirated from the troughs and the strips were washed as in 
previous washing step 
10. Then 2 ml of substrate BCIP (5-Bromo-4-chloro-3-indole-phosphate)/NBT 
(nitroblue tetrazolium) was added to each trough. It was covered and incubated 
for 15 minutes on rocking platform. The antigen-antibody reaction can be 
visualized by the presence of different bands.  
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11. The substrate was aspirated and the reaction was stopped using distilled water.  
12. The strips were dried and graded based on the different bands.  
For the run to be valid the bands on the controls must be satisfactory 
 Non-reactive control 
o The band for serum control should be visible and there should be no HIV-
1 or 2 specific bands 
 Weak reactive control 
o It measures the sensitivity of the kit. The serum control band along with 
weak bands at p24 and or gp41 and gp120/gp160 
 Strong reactive control 
o Serum control band along with bands at p17, p24, p31, gp41, p51, p55, 
p66, gp120/gp160 must be visualized. Also HIV-2 specific band should 
be visible. 
Interpretation 
The presence or absence of antibodies to HIV-1 is graded by comparing with the assay 
control strips tested with negative or non-reactive control, weak reactive and strong 
reactive controls. The different grades are negative, 1+, 2+, 3+ and 4+.  
An American Red Cross criterion was used for the interpretation of the assay. 
5.3. Statistical analysis 
The data generated from study samples of controls and HIV-1 infected individuals were 
analyzed using independent sample ‘t’ test. The data obtained from western blot was 
analyzed using chi square test. The data generated from the archived paired sera of HIV-
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1 infected individuals before treatment, after treatment and following virological failure 
were analyzed using paired ‘t’ test. The data generated from these samples using these 
statistical methods were plotted using Box and Whisker plot. The comparison of the 
performance of the in-house assay with limiting antigen avidity assay was done by using 
degree of agreement kappa. The independent sample ‘t’ test, the paired sample ‘t’ test, 
degree of agreement was done using MedCalc Statistical Software v. 14.8.1 (MedCalc 
Software, Belgium; http://www.medcalc.org). The analysis of all demographic and 
laboratory data were performed using Microsoft Excel 2013. A p value of < 0.05 was 
considered significant.  
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5. Results 
The findings on HIV-1 infected individuals (Group 1) and HIV-1 negative individuals 
(Group 2) 
Demographic details 
There were 896 volunteers who came to ICTC of a tertiary care centre during the study 
period - August 2015 to July 2016. All of them were tested according NACO strategy 
3. Of these 132 individuals were found to be positive for HIV (14.73%). This data is 
shown in Fig 7.  
 
Figure 7: Distribution of volunteers (n = 896) to ICTC from August 2015 to July 2016, 
and showing the number of positive and negative samples month wise 
Among these 117 treatment naïve HIV-1 infected individuals were recruited for the 
study. The remaining 15 were individuals who refused consent, or below the age of 18 
years and one of the individuals had HIV-2 infection. 
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These HIV-1 infected individuals (n = 117) were from different states of the country, 
majority were from Tamil Nadu (n=47, 40.17%) followed by Andhra Pradesh (n=21, 
17.95%) and West Bengal (n=18, 15.38%). There was also one individual from 
Bangladesh. The rest of the HIV-1 infected individuals were from other regions as 
shown in the Table 7. 
Table 7: Geographic distribution of the HIV-1 infected individuals in the study (n= 
117) 
Geographic region Number (%) 
Tamil Nadu 47 (40.17%) 
Andhra Pradesh 21 (17.95%) 
West Bengal 18 (15.38%) 
Jharkhand 15 (12.82%) 
Bihar 4 (3.42%) 
Chhattisgarh 3 (2.56%) 
Uttar Pradesh 3 (2.56%) 
Assam 2 (1.71%) 
Manipur 2(1.71%) 
Karnataka 1(0.85%) 
Bangladesh 1 (0.85%) 
Total 117 (100) 
 
The gender distribution of the HIV-1 infected individuals (n = 117) recruited for the 
study is represented in Fig 8. 
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 Figure 8: Distribution of HIV-1 infected individuals in the study population by gender  
(n =117) 
The age group of the HIV-1 infected individuals (n = 117) ranged from 20-68 years 
with the mean age being 40 years (mean age in females = 38yrs; males = 41yrs). The 
age distribution of HIV-1 infected individuals in the study is shown in Table 8. 
Table 8: Age distribution of HIV-1 infected individuals in the study (n = 117) 
Age group in years Number (%) 
21-30 23 (19.66%) 
31-40 41 (35.04%) 
41-50 41 (35.04%) 
51-60 10 (8.55%) 
61-70 2 (1.71%) 
Total 117 (100.00%) 
In HIV-1 infected individuals of the study population, the transmission was 
predominantly through sexual contact as shown in Fig 9. 
67
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Figure 9: Mode of transmission among HIV-1 infected individuals in study population 
(n=117) 
Of 113 who acquired HIV-1 infection by sexual transmission, the mode of acquisition 
is shown in Fig 10.  
 
Figure 10: Pie chart showing the source of acquirement of infection in HIV-1 infected 
individuals who acquired the infection sexually (n=113) 
The predominant mode of acquisition of infection in males and females were associated 
with high risk behavior and infection from spouses respectively as shown in Fig 11. 
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Figure 11: Mode of acquisition of HIV-1 infection in sexually transmitted HIV-1 
infection, Males (n = 66), females (n = 47) 
Group 2: 
Among the volunteers who were recruited from ICTC as HIV negative controls, the 
male and female distribution is depicted in Fig 12.  
Figure 12: Distribution of HIV negative individuals recruited as controls for study by 
gender (n = 40) 
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The age of the HIV negative individuals recruited for the study ranged from 18-60 years 
with mean age being 36 years (mean age in males = 38 years and mean age of female 
=36 years). Majority of them were from Tamil Nadu (n = 28, 70%) like the HIV-
1infected individuals. The state distribution of these HIV negative individuals are 
shown in Table 9.                   
Table 9: Geographic Distribution of HIV negative individuals recruited as controls 
(n=40) 
States Number (%) 
Tamil Nadu 28 (70%) 
Andhra Pradesh 5 (13%) 
Jharkhand 2 (5%) 
West Bengal 1 (3%) 
Kerala 1 (3%) 
Karnataka 1 (3%) 
Assam 1 (3%) 
Bihar 1 (3%) 
Total  40 (100%) 
LAg Avidity Assay  
All blood samples of HIV-1 infected individuals and the HIV negative controls in the 
study population were tested using the LAg Avidity EIA following the manufacturer’s 
instructions.  
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The HIV negative controls and samples positive for p24 antigen alone and negative for 
HIV-1 IgG were tested along with positive samples as internal negative control and all 
these samples were negative in the assay. The mean normalized optical density (ODn) 
value of these controls were 0.068 ± 0.03. 
The mean ODn value of samples positive for p24 alone were 0.131 ± 0.05. 
Both control and p24 positive ODn results fell in the negative control range (0-0.240) 
according to the LAg avidity EIA.  
The ODn values between the controls and HIV-1 infected individuals is depicted in Fig 
13. 
The mean ODn value of samples of HIV-1 infected individuals was 3.549 ± 1.1. 
Figure 13: Box and Whisker plot showing the distribution of ODn values of the HIV 
negative controls (n=40) and HIV-1 infected individuals (n=117) in the study 
population 
p < 0.0001 
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Samples of the HIV-1 infected individuals were tested and the results are shown in Fig 
14. 
Figure 14: The different ODn value status of the samples from HIV-1 infected 
individuals in the study population using the LAg Avidity EIA 
 
Of 117 samples tested, 8 (6.84%) were found to recently infected (less than 6 months) 
as described by the manufacturer.  
The comparison between the ODn values of recent infection and long term infection is 
shown in Fig 15. 
The mean ODn value was significantly lower for recent infections compared to long 
term infections (ODn 0.662 ± 0.42 vs 3.761 ± 0.84, p <0.0001). 
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Figure 15: Box and whisker plot between ODn values of recent and long term infection 
ODn cutoff 1.5 using the LAg avidity EIA 
Variability 
The inter and intra-assay coefficient of variation for the LAg avidity EIA for individuals 
with recent HIV-1 infection was carried out and there was no significant difference in 
% CV observed. This data is shown in Table 10. 
 
 
 
 
 
 
p < 0.0001 
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Table 10: Inter-assay and intra-assay variability of the LAg avidity EIA using 
samples of individuals with recent infection 
Sample ID 
Inter – assay coefficient 
of variation (CV%) 
Intra – assay coefficient 
of variation (CV %) 
LAV 8 8% 5% 
LAV 31 8% 6% 
LAV 43 13% 1% 
LAV 48 4% 13% 
LAV 55 25% 3% 
LAV 104 13% 4% 
LAV 110 4% 3% 
LAV 117 10% 7% 
Mean % CV of the assay  11% 5% 
 
Among the 8 individuals who were found to be recently infected by the LAg assay 5 
got infection form the infected spouse and three got it through sexual exposure with 
commercial sex workers. The details on these 8 individuals are shown in Table 11. 
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Table 11: Details about individuals who are recently HIV-1 infected (n = 8) 
 Age/ 
Sex* 
Marital 
Status 
Occupation Exposure Trans-
mission 
from  
spouse 
High  
risk  
behavior 
State ODn 
1 38/F Married Laborer  Sexual Yes No Tamil Nadu 0.807 
2 68/M Married Business Sexual No Yes Jharkhand 1.354 
3 36/F Married Housewife Sexual Yes No Tamil Nadu 0.166 
4 39/M Married Business Sexual No Yes Andhra 
Pradesh 
0.353 
5 34/F Married Housewife Sexual Yes No Andhra 
Pradesh 
0.845 
6 32/M Married Driver Sexual No Yes Jharkhand 0.183 
7 35/F Married Laborer Sexual Yes No Tamil Nadu 0.974 
8 39/F Married Housewife Sexual Yes No Jharkhand 0.612 
 
 
In-house avidity assay 
The results of in house are interpreted based on the avidity index (AI). The distribution 
of the AI of the 117 HIV-1 infected individuals is depicted in the Fig 16.  
*M= Male, F= Female 
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Figure 16: Distribution of Avidity Index for HIV-1 infected individuals (n =117) using 
the in-house avidity assay 
The comparison of the avidity index (AI) between the recent and long term infection in 
the study population was carried out. The cutoff for HIV-1 infection to be recent and 
long term was AI ≤0.80. The mean AI is significantly lower for recent than long term 
infection (0.494 ±0.18 vs 0.992 ±0.09, p < 0.001). This data is shown in Fig 17. 
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Figure 17:Comparison between recent (n = 9) and long term infection (n = 108) based 
on Avidity Index (AI) cutoff 0.80 using the in-house avidity assay 
The comparison between LAg avidity EIA and in-house avidity assay of 117 samples 
from HIV-1 infected individuals is shown in Table 12. 
Table 12: The comparison between LAg Avidity EIA and in-house avidity assay of 
117 samples from HIV-1 infected individuals  
 
LAg Avidity EIA 
Total Positive Negative 
In house assay positive 8 1 9 
In house assay negative 0 108 108 
Total 8 109 117 
 
 
p < 0.0001 
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With LAg avidity EIA as gold standard the accuracy indices of in-house avidity assay 
was calculated and showed good sensitivity and specificity. This data is shown Table 
13. 
Table 13: The accuracy indices of the in-house avidity assay in comparison with 
the commercial LAg avidity EIA   
Sensitivity 100 % (95% CI 63.06-100%) 
Specificity 99.08 % (95% CI 94.99-99.98%) 
Positive Predictive value (PPV) 88.89 % (95% CI 51.75-99.72%) 
Negative Predictive value (NPV) 100 % (95% CI 96.64-100%) 
 
The degree of agreement between the with LAg avidity EIA and the in-house avidity 
assay was calculated using the Kappa test and showed a significant agreement between 
the assays and is shown in Table 14. 
Table 14: The degree of agreement between the with LAg avidity EIA and the in-
house avidity assay calculated using the Kappa test 
Degree of agreement (κ) 0.94 
Standard deviation (Z) 10.15 
Probability (p) <0.0001 
 
Variability  
The inter and intra-assay coefficient of variation of the in-house avidity assay for 5/8 
samples of the individuals with recent infection is shown in Table 15. 
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Table 15: Inter-assay and intra-assay variability of the in-house avidity assay for 
samples of individuals with recent infection 
Sample ID 
Inter-assay coefficient of 
variation (CV%) 
Intra-assay coefficient of 
variation (CV%) 
LAV 8 8.0% 0.70% 
LAV 31 12.8% 13.53% 
LAV 43 2.4% 2.13% 
LAV 48 0.4% 1.08% 
LAV 55 1.8% 2.12% 
LAV 104 21.5% 14.23% 
Mean % CV 7.82% 5.6% 
 
Western Blot 
In every run of Western Blot, a non-reactive, weak reactive and strong reactive sample 
was tested. In negative control, only serum band was formed. Weak reactive control 
had less bands compared to strong reactive controls, the bands were more in number in 
strong reactive controls. The intensity of the band was also more. When reading was 
taken the numbered end of the strip was placed at the bottom as shown in Fig 18 a. And 
the various bands were identified using the aid provided by the manufacturer which is 
shown in Fig 18 b. The bands for which intensity was 2+, 3+ and 4+ was considered as 
positive for antibodies to that particular antigen 
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Figure 18: Western Blot of the negative control, weak reactive, strong reactive, samples 
of individuals with recent and long term infection. In negative control, only serum band 
was formed. Weak reactive control had less bands compared to strongly reactive 
controls, the bands are more in number. The intensity of the band was also more. In 
recent infections the bands were fewer and intensity of bands is less when compared to 
long term infection. The figure b shows a card which was used to identify the various 
bands which had developed. 
Western blot analysis of the samples of HIV-1 infected individuals with recent infection 
showed weak band or no band against pol proteins – p31, p51 and p66, when compared 
to those with long term infection. Summary of the western blot analysis in HIV-1 
infected individuals (n=117) is shown in Table 16. 
 
b a 
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Table 16: Western Blot reactivity to the different antigens in HIV-1 infected 
individuals with recent (n = 8) and long term infection (n = 109) 
 
Group 3 – HIV-1 infected individuals before ART and after responding to 
ART, (n = 25) 
Demography  
In group 3, HIV-1 infected individuals before treatment with ART and following 
initiation of ART (n = 25) majority were men (76%), the gender distribution of these 
individuals is shown in Fig 19. 
Antibodies 
to 
Recent infection 
(n = 8) 
 
Long term infection 
(n = 109) 
p 
value 
Negative/Weak* 
 
Positive# Negative/Weak* 
 
Positive# 
 
p17 7 (87.5%) 1 (12.5%) 78 (71.6%) 31 (28.4%) 0.57 
p24 0 8 (100%) 8 (7.3%) 101 (92.7%) -- 
p31 6 (75%) 2 (25.0%) 24 (22%) 85 (78%) 0.004 
p39 7 (87.5%) 1 (12.5%) 72 (66.1%) 37 (33.9%) 0.39 
gp41 4 (50.0%) 4 (50.0%) 3 (2.8%) 106 (97.2%) -- 
p51 6 (75.0%) 2 (25.0%) 39 (35.8%) 70 (64.2%) 0.07 
p55 8 (100%) 0 83 (76.1%) 26 (23.9%) 0.26 
p66 3 (37.5%) 5 (62.5%) 12 (11%) 97 (89%) 0.10 
gp120 1 (12.5%) 7 (87.5%) 0 109 (100%) -- 
gp160 0 8 (100%) 0 109 (100%) -- 
*Weak = Intensity of band is 1+, #Positive = Intensity of the band 2+ and more 
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Figure 19: The gender distribution of the HIV-1 infected individuals (n = 25) of group 
3 - Before treatment with ART drugs and following the initiation of treatment and 
responding to the same.  
We used archived paired serum samples of HIV-1 infected individuals before treatment 
with ART and 6-12 months following initiation of ART and responding to the same. 
The viral load of these individuals after responding to 6-12 months of ART were below 
detection limit or the logarithmic difference of the viral load before and after ART were 
more than 1. The viral loads of HIV-1 infected individuals before treatment with ART 
and following the initiation of treatment after and responding to the same is shown in 
Table 17. 
 
 
 
 
19, 76%
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Table 17: The viral loads (VL) of the HIV-1 infected individuals before ART and 
following initiation of ART (n = 25) 
Age 
(Years) Sex* 
VL before 
ART 
VL after 
ART 
log diff 
of VL 
Treatment 
period 
36 M 156,491 2,857 1.74 1 year 
25 F 68,210 1,575 1.64 1 year 
46 F 52,767 1,012 1.72 1 year 
62 M 77,043 754 2.01 6 months 
27 M 87,202 279 2.49 1 year 
39 M 131,461 251 2.72 1 year 
44 M 728,815 218 3.52 1 year 
35 M 169,337 179 2.98 1 year 
34 M 12,947 <72 2.26 1 year 
30 M 4,462 <72 1.80 1 year 
41 M 188 <72 0.42 1 year 
36 M 552 <72 0.89 1 year 
52 M 47,413 <72 2.82 1 year 
43 M 21,717 <72 2.49 1 year 
30 M 35,212 <72 2.70 1 year 
49 M 121 <72 0.23 1 year 
38 M 25,107 <72 2.55 1 year 
44 M 121 <72 0.23 1 year 
41 M 21,884 <72 2.49 1 year 
45 F 646,481 <72 3.96 1 year 
34 M 21,206 <72 2.48 1 year 
66 M 68,009 <72 2.98 1 year 
30 F 26,996 <72 2.58 1 year 
40 F 3,724 <72 1.72 6 months 
26 F 2,917 <72 1.61 1 year 
 
The mean ODn values of samples from HIV-1 infected individuals (n=25) responding 
to treatment was significantly lower than the samples prior to treatment (ODn = 
3.977±1.1 Vs ODn = 4.306± 0.97, p=0.0038) as shown in Fig 20. 
*M = Male, F = Female 
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Figure 20: Box and whisker plot of ODn value of HIV-1 infected individual before ART 
and after responding to ART (n=25) 
 
Group 4 – HIV-1 infected individuals responding to ART and following treatment 
failure (n = 7) 
HIV-1 infected individuals (n = 7) responding to ART had viral load below detection 
limit. The viral loads of HIV-1 infected individuals when they were responding to ART 
and after they developed virological failure is shown in Table 18. 
 
P = 0.0038 
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Table 18: HIV-1 infected individuals responding to ART and after developing 
virological failure (n = 7) 
Age Sex 
VL* after 
responding 
ART 
 
Treatment in 
years 
VL* after 
virological failure 
49 Male <40 8 129,233 
42 Female <40 5 32,293 
46 Male <40 4 827,829 
48 Male <40 9 191,885 
45 Female <40 9 1,108,938 
30 Male <40 5 21,174,000 
43 Male <72 4 528,647 
 
There was an increase in the mean ODn values when individuals (n=7) responding to 
ART had virological failure compared to when they were responding to ART (ODn = 
4.128±0.6 vs ODn = 3.144±1.2, p = 0.057) is shown in Fig 21. 
Figure 21 : Box and whisker plot of ODn values in HIV-1 infected individual when they 
were responding to ART and after developing virological failure (n=7) 
*VL = viral load 
p = 0.057 
  
70 
 
6. Discussion 
Human Immunodeficiency Virus infection is a major health problem worldwide. It has 
claimed more than 35 million lives so far. In 2015, there were about 36.7 million people 
living with HIV globally(2). There is no known cure available for HIV infection but 
there are many effective antiretroviral drugs to control the infection and help in 
prevention. HIV-1 is known to cause a more severe disease than HIV-2(11). The 
knowledge about the routes of transmission helps us to introduce effective strategies for 
prevention. The awareness of the spread of HIV infection among different groups is 
important, so that immediate interventions can be introduced in the most effective 
manner to reduce the spread of infection. HIV incidence is the rate at which a population 
acquires HIV infection and it measures the magnitude of current HIV transmission. In 
order to know HIV-1 incidence, we need accurate assays for differentiating between 
recent and long term infections (12). In 2015, the number of new HIV infections was 
about 2.1 million worldwide(2). India had an estimate of 86,000 new HIV infections(6). 
Knowing the HIV-1 incidence helps us in program planning, population surveillance, 
evaluation of the effectiveness of current intervention programs and selecting 
population for clinical trial for new preventive intervention or early treatment(12). 
In our study carried out during August 2015 to July 2016, of 896 volunteers who came 
to ICTC of a tertiary care centre, 132 (14.73%) was positive for HIV infection. All these 
individuals were tested according to NACO strategy 3. Among the volunteers who 
attended the ICTC, HIV-1 infection were seen more in men (57%) compared to women 
(43%) which was comparable with the national data where 40.5% of the total HIV 
infection were in women (6). In our study, the infection was more common in men and 
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women in ages 31-50 years (70%). In India, children (below 15 years) accounted for 
12% (10,400 of 86,000) of total new infections while 88% (75,900 of 86,000) new 
infections were among individuals above 15 years of age(7). The mode of transmission 
in 96% of the individuals in the study population was through sexual contact. Blood 
transfusion associated HIV-1 infection was only 2% and in remaining 2% the route of 
transmission was unknown. In India, the incidence of blood donor sero-reactivity has 
reduced from 1.2% to 0.2% in blood banks supported by NACO(6). In blood bank a 
single test of high sensitivity is used for HIV reactivity. Highly sensitive tests increase 
the chance of false positives but it reduces the chance of missing an HIV infection. So 
if an individual tested positive in a blood bank screening test, then the individual is 
referred to ICTC for confirmation(53). In rural areas of certain states like Uttarakhand, 
Uttar Pradesh, Jharkhand, Bihar and Chhattisgarh, the access to safe blood is limited(6). 
One of the HIV-1 infected individual who acquired the infection by blood transfusion 
was from Jharkhand. Sexual transmission was associated with high risk behavior in 
57% of the HIV-1 infected individuals (n=117) and 42% acquired the infection from 
their HIV-1 infected spouses and in 1% high behavior or spouse’s history unknown. 
Among the HIV-1 negative controls, there were more women (60%) than men (40%), 
this can be probable due to the fact that some of these women have come to get tested 
as their spouses are positive for HIV infection. 
Identification of the recent HIV-1 infection is important because it helps us to assess 
the incidence of HIV infection in the population(12). It helps us to identify the groups 
who are at higher risk of acquiring new HIV infection and to direct health campaigns to 
target them. It helps us in contact tracing and can also help us to the assess the 
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effectiveness of our intervention programmes(12,15). Clinically it is difficult to identify 
recent infection as most of them are asymptomatic but highly infectious. Also, one of 
the components of global strategy for prevention and assessment of HIV drug resistance 
is to check for transmitted drug resistance in recently infected populations(90). 
Janssen et al (57) first reported a laboratory test for differentiating recent HIV-1 
infections from established infections. They developed and validated a serological 
testing algorithm in which HIV-1 infected individuals had reactive result on a sensitive 
HIV-1 EIA (3A11 assay, Abbott, Illinois, USA) but nonreactive results on a less 
sensitive (LS) EIA which was a modification of the same EIA (3A11-LS assay). These 
individuals were identified as having early HIV infection. For the less sensitive EIA, 
they modified the sample dilution, sample incubation time, and conjugate incubation 
time. Their assay diagnosed 95% of the recent infection but misdiagnosed 0.4% with 
long term infection and 2% with late-stage AIDS (severe immunosuppression) as 
having a recent HIV-1 infection. There were many other studies on less sensitive 
immunoassays but all assays based on this principle had used antigen from HIV-1 
subtype B and not reliable for subtype C prevalent in India(65,66,70). 
To overcome this subtype bias, Parekh et al (58) devised BED capture EIA (BED CEIA, 
(Calypte Biomedical Corporation, Oregon, USA) which detected the increasing levels 
of HIV-1 specific IgG after seroconversion and which could be used for detecting recent 
HIV-1 infection. They used synthetic protein which had immunodominant regions of 
gp41 from HIV-1 subtypes B, E, and D as antigen. The proportion of the HIV-1 
immunoglobulin G to total immunoglobulin G gradually increased for 2 years following 
seroconversion. The assay had high false recency rate (FRR). Moyo et al (95) evaluated 
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false recent rates of HIV-1 subtype C incidence in Botswana using the BED CEIA 
(Calypte Biomedical Corporation, Oregon, USA), a Bio-Rad Avidity Index (BAI) assay 
(modification of the Bio-Rad HIV1/2+O EIA, Bio-Rad Laboratories, Washington, 
USA). The false recent rate mean values for BED CEIA was 6.05% (95% CI 4.15–
8.48), Bio-Rad Avidity Index was 5.57% (3.70–8.0). The inter-assay agreement 
between BED capture EIA and Bio-Rad avidity index was 92.8% (95% CI 90.1–94.5) 
for recent/long-term infection. 
In the study reported in this thesis, of the recruited population, 8 (6.84%) were found to 
be recently infected that is ODn value <1.5. According to a study by Duong et al (87) 
the mean duration of recency (MDR) in LAg avidity EIA (Sedia, Oregon, USA) for 
ODn = 1.0 was 88-94 days and for ODn = 2.0 was 177-183 days; and the overall 
proportion of false recent rate increased from 0.6% to 2.5% when cutoff of ODn was 
increased from 1.0 to 2.0. So in order to balance between longer mean duration of 
recency and smaller false recency rate (<2%), they suggested a cutoff ODn = 1.5,  which 
represented a mean duration of 130 days(87). In our study, except for one individual all 
the other recently infected individuals (n = 7) had ODn <1.0 and would have acquired 
the infection in the last 3 months. While in BED capture EIA, the cutoff for ODn was 
0.80, so if ODn ≤ 0.80 it was considered as recent seroconversion and if ODn >0.80 it 
was considered as long term infection. In BED CEIA, ODn = 0.8 corresponded to a 
mean duration of recency of 197 days (55). Among the recently infected individuals (n 
= 8) all of them acquired the infection by heterosexual transmission. 7 (87.5%) of them 
belonged to the age group 31-40 years and 1 belonged to age group 61-70 years. In 
them, 5(62.5%) were females and acquired the infection from their HIV-1 infected 
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spouses and 3 (37.5%) males acquired the infection through high risk behavior. Among 
the recently infected men, two of them were from Jharkhand, one of them a driver and 
another business man who travels a lot and have got the infection from commercial sex 
workers. This suggests the importance of curbing the infection in high risk groups 
because they serve as a huge pool of HIV infection in our community. From the high 
risk group, the HIV infection is transmitted to the bridging population which includes 
long distance drivers and migrant population. From bridge population it goes to their 
spouses or sexual partners. It is very important to identify the HIV infection in 
individuals but it is even more important to identify the individuals with recent infection 
as they will have a very high viral and are more infectious(96,97).  Studies show that 
individuals who are recently infected with HIV tend to be more engaged in high risk 
behaviour than individuals who has had long term HIV infection(98–100). 
There was not much national data available for frequency of recent infections. Hall et 
al(74) in United States tested 6864 of  HIV-1 positive specimens using the BED assay 
and classified 31% (2133) as recent infection. Compared to our study where we had 
only 6.83% rent infections, they had 31% recent infection but their sample size was 
large and covered almost 22 states in United States. One of the reasons for the low 
incidence in our study was because many of the volunteers in our ICTC were spouses 
of already diagnosed HIV infected individuals.  A study by Simmons et al (101) in 
Ukraine during 1 year tested 446 newly diagnosed HIV-1 infected individuals using 
LAg avidity assay, 39 (8.7%) were classified as recent infection with ODn < 1.5. But 
of these 39, 10 were reclassified as long term infection as their viral load was less than 
1000. So, there were 29 (6.5%) individuals with recent infection. Preliminary studies 
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by Parekh et al(86) and Duong et al(64) using the LAg assay suggested a good 
reproducibility with coefficient of  variation <10%. In our study the mean inter-assay 
and intra-assay coefficient of variation of LAg avidity assay for samples of individuals 
with recent HIV infection was 11% and 5% respectively.  
One of advantage of the LAg avidity assay over other assays for recent infection was 
that it used recombinant protein as antigen. This protein contained the major subtypes 
and recombinants of gp41 immunodominant region of HIV-1 group M. It overcame the 
limitation of less sensitive assay which used only HIV-1 subtype B and of BED CEIA 
which used only antigen against HIV-1 subtypes B, E and D. In India, HIV-1 subtype 
C is more prevalent(32). The wells of LAg are coated with the recombinant antigen in 
limiting concentrations because at high concentration of antigen, IgG antibodies with 
low and high avidity bind to the antigen and binding occurs with the help of both 
binding sites of the antibodies. When the concentration of the antigen is lowered, only 
binding of antibodies with high avidity is permitted and as concentration of the antigen 
is limited binding at both sites simultaneously is not possible so the antibodies with low 
avidity would be able to bind strongly(16). Even though there are many commercial 
assays for identifying recent infections, we found the need to develop an in-house as 
the cost of these assays are very high and not affordable by every laboratory. One of the 
issues we had with the LAg avidity assay was its high cost. So we decided to use an 
indigenous commercial assay and develop an in-house by modifying it. 
Wei et al (16) developed a new recombinant protein which could detect antibodies 
against all recombinants and major subtypes of HIV-1 group M; the recombinant 
protein was derived from immunodominant region (IDR) of glycoprotein41 of the 
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respective subtypes . The recombinant protein (rIDR-M) was expressed in Escherichia 
coli. It was equally reactive with HIV-1 antibodies of the different subtypes and 
divergent subtypes B and AE. In their study, they used recombinant protein in two assay 
formats to measure avidity of the antibody. One was a two-well avidity index that is a 
single sample required two wells for the test and second assay format was a one-well 
limiting antigen avidity assay. In both assays they used buffer with pH 3.0 to dissociate 
antibodies with low avidity. They found that recent HIV-1 infection could be detected 
with or without dissociation agent when the concentration of the antigen was limited. 
Also, the one-well limiting antigen avidity EIA permitted more samples to be tested 
over the two-well avidity index -EIA. And both these assays were better than the 
available commercial assays as they used a recombinant protein which prevented the 
subtype based performance(16). The detection ability of the assay was more efficient 
when dissociation buffer with pH 3.0 was included. In our study, initially the 7M urea 
solution that we used for the in-house assay had a pH = 6.4 and we found that it didn’t 
dissociate the low avidity antibodies giving us an almost equal OD value with and 
without urea treatment. When we changed the pH to 3.0, the urea solution worked and 
it dissociated the low avidity antibodies giving us a decrease in OD value with urea 
treatment.   
Suligoi et al (60) had evaluated the precision and accuracy of the avidity index (AI) 
calculated on an automated 3rd generation micro particle EIA (AxSYM  HIV 1/2gO 
assay from Abbott). They used guanidine as the dissociation agent for separating the 
low avidity antibodies, they duplicated each sample and one in phosphate buffered 
solution and one in 1M guanidine (1:10). They had evaluated the precision by 
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performing the test on multiple replicates of 8 HIV-1 serum samples and evaluated the 
accuracy in identifying recent infections (< 6 months of seroconversion) using 216 
serum specimens from 47 individuals whose seroconversion dates were known. They 
evaluated the sensitivity and specificity of the procedure for different avidity index 
cutoff values. This modification of 3rd generation assay can be an accurate tool for 
classifying recent and long term infection. 
In another study Suligoi et al (59) compared the avidity index between an automated 3rd 
and 4th generation immunoassays (AxSYM HIV 1/2 gO; Abbott Diagnostics vs 
Architect HIV Ag/Ab Combo; Abbott Diagnostics). The fourth generation assay detects 
both HIV-1 p24 antigen and antibodies. They used 142 samples collected from 75 HIV-
1 infected individuals whose seroconversion dates were known. They found that both 
assays showed 91.5% accuracy in identifying recent HIV-1 infection using AI < 0.80 
and the 4th generation was found to slightly more sensitive (89.4% vs 84.8%, p > 0.05) 
and but less specific (93.4% vs 97.4%, p > 0.05). The correlation (R) between assays 
was 0.87. The accuracy of AI with Architect HIV Ag/Ab Combo was 94.7%, when they 
excluded 20 specimens which fell in the gray zone area near the cutoff (0.75 < AI < 
0.84) and the agreement between the two assays was found to be 99.2%. 
All 117 samples which were tested using LAg avidity assay was used and tested using 
the in-house avidity assay. This in-house avidity assay was a modification of a second 
generation enzyme immunoassay (Microlisa, J. Mitra diagnostics, New Delhi) and the 
wells were coated with gp41, gp120 for HIV-1 and gp36 for HIV-2. The cut off was set 
as < 0.80 based on study by Suligoi et al (59,60,102). The assay picked up 9 samples 
with AI <0.80. All the recently infected classified according to LAg avidity assay had 
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an avidity index of <0.80. The extra sample picked up by the in-house avidity assay had 
AI=0.73 in the in-house avidity assay and ODn = 2.11 in the LAg avidity assay. The 
mean AI was significantly lower for recent than long term infection (0.49 ±0.18 vs 0.99 
±0.09, p < 0.001).  The sensitivity of the in house assay was 100% (95% CI 63-100%) 
and the specificity of the assay was 99.08% (95% CI 94.99- 99.98%) when compared 
to the LAg avidity assay. The positive and negative predictive value were 88.89% (95% 
CI 51.75-99.72%) and 100% (96.64-100%) respectively. The degree of agreement 
between the two assays was 0.94 with probability of <0.0001. Our in-house avidity 
assay showed good reproducibility with an inter-assay coefficient of variation of 7.82% 
and intra-assay coefficient of variation 5.6% for samples of individuals with recent 
HIV-1 infection. 
Gao et al (88) developed a limiting antigen avidity dot immune gold filtration assay. It 
is rapid membrane based immunodiagnostic assay and compared to the enzyme 
immunoassay, they were more suitable for onsite testing because it is rapid, economical 
and convenient. The sensitivity and accuracy of the assay was increased by adding a 
silver staining.  Its agreement with LAg avidity assay was κ = 0.75 which was less 
compared to the agreement of the in-house assay used in our study with LAg avidity κ 
= 0.94. 
Thomas et al (45) studied the maturation of avidity of IgG antibodies to the different 
antigen gp41, p24 and p17. They found that antibodies to gp41 are more reliable than 
antibodies to p17 and p24. Antibodies to gp41 reflects time since first detection of 
antibodies in all cases. Whereas antibodies to p17 and p24 was not so reliable during 
the same time period. Also, when individual was on ART the avidity of gp41 antibody 
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remained high but avidity of anti-p24 fell before onset of AIDS. The in-house assay we 
used in our study had gp41 and C terminus of gp120 coated in the wells. Suligoi et al 
(59,60) used 1M guanidine as the chaotropic agent to separate the weak bonds between 
the antibody and antigen and followed the manufacturer’s after that. Shepherd et al(15) 
used 7M urea as chaotropic agent in their study. In our study we used 7M urea at pH=3.0 
for dissociation. The sensitivity (100%) and specificity (99.08%) was comparable with 
the avidity assay developed by Shepherd et al(15), they had sensitivity and specificity 
of 100% and 98.65% respectively. Their assay was a modification of Genscreen HIV1/2 
(Bio-Rad, Marnes-la-Coquette, France). 
The in-house assay we used had many advantages over other assays used for classifying 
recent and long term infections. It is microtitre plate assay which uses equipment 
available in most basic virology laboratories. It does not require expensive and large 
automated platform. It is easy to transfer the assay between laboratories and so can be 
used in local laboratories rather than reference laboratory for testing for recent infection. 
The in-house assay requires very small amount of sample when compared to automated 
platforms. It uses a simple and easy modification in the commonly available commercial 
assay. The quality control issues are overcome through the good quality control of the 
commercial assay. The good sensitivity for recent infection can help in prioritizing for 
contact tracing and help to minimize the transmission of the infection in early stages as 
the individuals are more infectious during this period. The in-house assay in our study 
is an indigenous assay with sensitivity 100% and specificity 99.5% and detects the 
presence HIV-1 subtype C which is prevalent in India(103). Standardizing the in house 
assay also reduces the cost of avidity testing in HIV-1 infection. 
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Western blot analysis of our study samples of recently infected individuals 
demonstrated low levels of antibodies to pol and gag proteins compared to those with 
long term infection. Re et al (17) study showed that even recently HIV-1 infected 
individuals who were treated had complete immunoblot response to envelope proteins 
within 6 months. This finding was similar to what we found in our study that even those 
individuals who were recently infected with HIV-1 were having developed bands to 
envelope protein. This suggests that antibodies to envelope proteins appear early in the 
disease and is maintained. In our study, individuals with recent infection had weak or 
no bands against pol proteins. There was low reactivity to p31, p51 and p66 in 
individuals with recent infection compared those with long term infection. There was a 
significant difference in reactivity to p31(p = 0.004) between individuals with recent 
and long term HIV infection and the probability value of p51 (p = 0.07) and p66 (p = 
0.10) just fell short of significance. Also the results suggest that antibodies to different 
antigens appear along the course of the disease and not simultaneously.(11).   
One of the aims of our study was look at the effect of antiretroviral treatment on the 
response to antibody maturation. In paired sample testing of HIV-1 infected individuals, 
the first sample was collected before initiation of antiretroviral therapy and the second 
sample was collected after 6 to 12 months and the individuals were responding to on 
ART. The mean normalized optical density (ODn) value from the paired samples of 
HIV-1 infected individuals before initiating ART and after responding to ART obtained 
using the LAg avidity assay showed a significant decrease (p=0.0038) in ODn (4.306± 
0.97 to 3.977±1.1). This may be attributed to the impaired production of the humoral 
immune response. ART seems to prevent the emergence of IgG antibodies as it 
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suppresses the viral replication so there is no persistent production of antigens to 
stimulate the immune system for production of antibodies(17,46).  
Suligoi et al (60) determined the effects of ART, advanced stage of the disease and low 
HIV viral load on the avidity index (AI) by analyzing 15 serum samples from 15 
individuals whose seroconversion dates were unknown. These samples were analyzed 
using a modified version of the automated 3rd generation micro particle EIA (AxSYM 
HIV 1/2gO assay from Abbott) where they initially took duplicates of a single sample 
and one he diluted in 1M guanidine and the other in phosphate buffered saline; after this 
they followed the manufacture’s instruction. Their results for the precision of the 
procedure had total variance of the AI < 10%. They found that the mean avidity index 
was significantly lower for samples obtained within 6 months of seroconversion than 
those obtained later (0.68 ±0.16 versus 0.99±0.10; P < 0.0001). The avidity index < 0.6 
had a sensitivity of 33.3% and a specificity of 98.4% whereas avidity index < 0.9 had a 
sensitivity and specificity of 87.9 and 86.3% respectively. They found that ART, low 
CD4-cell count and low viral load had no apparent effect on the AI. 
Study done by Re et al (17) in Italy evaluated the antibody avidity and Western Blot 
pattern in recently infected HIV-1 individuals with early ART and not on ART.       
Thirty-six seroconverters were followed over 2 years. They were divided into two 
groups, one included 19 HIV-1 infected individuals not on treatment and second group 
included 17 individuals who were treated within 3 months of seroconversion. Their 
results showed a significant (p=0.03) lower reactivity to HIV-1 pol proteins and gag 
proteins and a lower mean value of the avidity index (0.66 vs 0.8, treated vs untreated) 
in individuals on ART. They also found that the treated individuals developed complete 
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western blot response within 6 months only to env proteins (gp41 and gp120). Antibody 
avidity maturation requires an active viral replication. Also the early initiation of ART 
prevents the gradual evolution of the avidity index of HIV-1 specific antibodies. 
A study by Selleri et al(46) in Italy evaluated the effect of ART in evolution of antibody 
avidity in 13 individuals with symptomatic primary HIV infection. Of the 13, 8 
individuals were on ART at diagnosis. The avidity index and western blot patterns was 
analyzed on plasma/ serum sample for one year. Among the 8 individuals, 4 individuals 
of them stopped ART subsequently. Their results showed that viremia in untreated 
individuals reached a set point in 4-6 months and in the treated cases there was a 
suppression of viremia and the viral load was undetectable during treatment. At 
diagnosis avidity index was low in both untreated (median AI = 0.42, range = 0.33-
0.43) and treated individuals (median AI= 0.44, range = 0.40-0.72). The individuals 
were followed up at 3,6 and 12 months and showed progressive increase in avidity index 
in untreated individuals but in all the individuals on ART it remained below 0.80(46). 
In a study by Wendel et al(18), they observed decrease in proportion of HIV-1 specific 
IgG when the HIV-1 infected individual had a viral suppression associated with 
antiretroviral therapy which was shown by the median decrease of 0.42 in normalized 
optical density in BED capture EIA (Calypte Biomedical Corporation, Oregon, USA) 
per year of antiretroviral therapy. They also found that avidity index was not affected 
by longer duration of antiretroviral therapy. 
In the study reported in this thesis the paired sample testing of HIV-1 infected 
individuals responding to treatment and had viral loads below detectable level and after 
they developed virological failure, there was an increase in the mean normalized optical 
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density (ODn) values (p=0.058) in LAg avidity assay when they had virological failure 
compared to when they were responding to ART (ODn 4.13±0.6 vs ODn 3.14±1.2). 
The significance fell short probably because of the small sample size. In a study by 
Wendel et al(18), they observed different patterns of BED CEIA normalized optical 
density values in HIV-1infected individuals with viral breakthrough (viral load > 1000 
copies/ml) associated with lack of adherence or drug resistance. The BED CEIA 
normalized optical density (ODn) values increased by a median ODn of 0.52 in HIV-1 
infected individuals (n= 9/20) when the viral load went above 1000 copies/ml and these 
BED CEIA ODn values returned to values before viral breakthrough when viral 
suppression was re-established. The BED ODn values increased by a median ODn of 
0.81 in HIV-1 infected individuals (8/20) at the visit after viral breakthrough (mean 322 
days after the viral breakthrough). In the remaining three HIV-1 infected individuals 
there was no difference in BED capture EIA ODn values with viral breakthrough. They 
also found that longer duration of viral breakthrough does not affect the avidity index. 
Selleri et al (46) demonstrated an increase in avidity index in 4 individuals who 
interrupted the antiretroviral therapy, the avidity index went more than 0.80 in less than 
6 months.  These HIV-1 infected individuals were on treatment and subsequently 
stopped. Our results have shown the similar results and establishes the fact that there 
can be increase in avidity when there was a virological failure. 
In conclusion, our study showed that 6.83% of the 117 HIV-1 infected attendees in 
ICTC are infected recently (less than 6months) by the LAg avidity assay. And the 
modified commercial assay in-house can be used as an alternative assay for detecting 
recent infection 
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7. Summary and Conclusion 
Summary  
The study was done to find the frequency of recent HIV-1 infections among the 
volunteers who attended ICTC of a tertiary care centre using LAg avidity EIA and to 
compare the results with an in-house assay and with HIV western blot antibody pattern. 
The other objective of the study was look at the effect of antiretroviral therapy on avidity 
maturation of HIV-1 specific immunoglobulin G among HIV-1 infected individuals. 
1. Among the 896 volunteers who were tested in ICTC, 132 (14.73%) were found 
to be positive for HIV infection.  
2. Of 132 individuals who were positive for HIV, 131 (99.24%) were positive for 
HIV-1 and 1 (0.76%) individual was positive for HIV-2. 
3. Eight (6.83%) individuals were found to be recently (< 6 months) infected using 
the LAg avidity assay among the 117 HIV-1 infected individuals recruited for 
the study. Among these 8 individuals with recent HIV-1 infection, 7 (87.5%) 
probably had a recent infection of less than 3 months based on the assay criteria. 
4. Of the 117 HIV-1 infected individuals recruited for the study, 40% were from 
Tamil Nadu, 18% were from Andhra Pradesh and 15% were from West Bengal. 
Among them 57% were men and 43% were women. 
5. Among the HIV-1 infected individuals (n = 117), 70% belonged to the age group 
31-50 years. 
6. Sexual contact was the predominant route of transmission in 96% of the HIV-1 
infected individuals (n = 117). Mode of acquisition of HIV-1 infection in 92.54% 
  
85 
 
of men was high risk behavior and 86% of women acquired the infection from 
their HIV-1 infected spouses. 
7. The mean normalized optical density (ODn) value of samples obtained with LAg 
assay from individuals with recent infections were significantly less than those 
with long term infection (ODn 0.662 ± 0.42 vs 3.761 ± 0.84, p <0.0001). 
8. The inter and intra-assay coefficient of variation for the LAg avidity assay were 
11% and 5% respectively. 
9. The accuracy indices of the in-house assay when compared with the LAg avidity 
assay were good with a sensitivity of 100% (95% CI 63.06-100%), specificity of 
99.08% (95% CI 94.99-99.98%) with positive predictive value of 88.89% (95% 
CI 51.75-99.72%) and negative predictive value of 100% (95% CI 96.64-100%). 
10. The in-house assay had a very good agreement κ = 0.94 with LAg avidity EIA 
(p<0.0001).  
11. The inter and intra-coefficient of variation of the in-house avidity assay was 
7.82% and 5.6% respectively for individuals with recent infection. 
12. The antibodies against pol proteins were less in those with recent infection 
compared to those with long term HIV-1 infection as detected by the Western 
Blot assay. 
13. The mean normalized optical density (ODn) values in the LAg avidity assay of 
samples from HIV-1 infected individuals (n=25) responding to treatment was 
significantly lower than the samples prior to treatment from the same individuals 
(ODn = 3.977±1.1 vs ODn = 4.306± 0.97, p=0.0038). 
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14. There was an increase in the mean normalized optical density (ODn) values 
obtained from the LAg avidity assay from samples of HIV-1 infected individuals 
(n=7) when responding to ART had virological failure compared to when the 
same individuals were responding. (ODn = 4.128±0.6 vs ODn = 3.144±1.2, p = 
0.057). The significance fell short probably because of the small sample size. 
Limitations 
Though LAg avidity assay can predict the mean duration of the recent infection, it 
cannot identify the exact month of infection. Samples from HIV-1 infected individuals 
with AIDS were not tested for checking the specificity of the assay. 
Conclusion 
In conclusion, the frequency of recent HIV-1 infection was 6.83% in newly diagnosed 
HIV-1 cohort. Antiretroviral therapy had a significant effect on avidity of HIV-1 
antibodies, possibly predicting virological failure.  The modification of the indigenous 
assay allows the availability of avidity testing for recent HIV-1 infection with low cost 
and is a good alternative to commercially available assay as it has good accuracy 
indices. 
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  PATIENT INFORMATION SHEET  
1. Study title: Human Immunodeficiency Virus Antibody Avidity Testing to identify recent infection 
among the newly diagnosed HIV-1 infected individuals and the effect of Antiretroviral Therapy on 
the Avidity Antibodies – A pilot study  
  
Please read this carefully. It tells you important information about the study. A member of the research 
team will explain you about your participation in this study. If you have any questions about the 
research or about this form, please ask us. If you decide to take part in this study, you must sign or 
provide your thumb impression in this form to show your willingness to take part in this study.  
Why is this study being done?  
Human immunodeficiency virus (HIV) weakens your immune system making you prone to many 
infections including those which normally doesn’t cause infection. HIV is transmitted sexually, through 
blood and blood products and also from mother to child before, during and after birth. It takes almost 8-
10 years for the person to be clinically symptomatic. India has the 3rd largest number of people living 
with HIV infection globally. The purpose of our study is find whether the person was infected recently. 
This will help us to find the group of people who are recently infected thereby focus on prevention of 
HIV infections among them.   
What will happen in this study?  
Individuals above 18 years, either sex, who are HIV-1 infected individual will be recruited in this study.      
If you agree to participate and you meet all the criteria required for the study as patient, a part of the 
blood sample already collected from you will be used for the study. 
Basic information, medical history and details of treatment will be collected from you.  
Will I be paid to take part in this study?  
You will not be paid for taking part in this research.  
What are the risks and possible discomforts from being in this study?  
There is no risk or discomforts. The consent is for using a part of the blood sample already collected 
from you for the study.  
What are the possible benefits from being in this study?  
By being a part of this study, you will not benefit directly with regard to the immediate management of 
the disease, but as a result of your participation, we will be able to identify the recently infected 
individuals among the HIV-1 infected individuals and minimize the transmission of the disease. 
 
 
If I take part in this research study, how will you protect my privacy?  
Information collected from you for this research study will be stored in the investigator’s research files. 
Your name and other information that might identify you will be recorded with a unique code number, 
protecting your identity and information from others. The research consent form that you sign may be 
inspected by the regulatory agencies or the Institutional Review Board in the course of carrying out their 
duties. If the signed research consent form is inspected or copied, the hospital will use reasonable 
efforts to protect your privacy. The results obtained from this study will be published in the scientific 
journals, but no information about your identity will be disclosed.  
If I have questions or concerns about this research study, whom can I call?  
You can contact the following person for your questions about the study  
Dr. Diviya Alex  
PG Registrar  
Department of Microbiology,  
Christian Medical College, Vellore - 632004  
Phone: 0416 2282588, 9940729250 
Informed Consent Form 
 
 
1. Study Title: Human immunodeficiency virus antibody avidity testing to identify recent 
infection among the newly diagnosed HIV-1 infected individuals and the effect of 
antiretroviral therapy on the avidity antibodies – A pilot study  
 
Study Number: ____________ 
 
Subject’s Initials: __________________ Subject’s Name: _________________________________________ 
 
Date of Birth / Age: ___________________________ 
 
  (Subject) 
 
(i)  I confirm that I have read and understood the information sheet dated ____________ for 
the above study and have had the opportunity to ask questions.   [  ] 
 
(ii)  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected. [  ] 
 
(iii)  I understand that the Sponsor of the clinical trial, others working on the Sponsor’s 
behalf, the Ethics Committee and the regulatory authorities will not need my 
permission to look at my health records both in respect of the current study and any 
further research that may be conducted in relation to it, even if I withdraw from the 
trial. I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published. [  ] 
 
(iv)  I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). [  ] 
 
(v)  I agree to take part in the above study. [  ] 
 
It may be possible to do special research tests related to HIV in the future if you agree 
to allow the specimen blood sample you have donated to be saved after the study is 
finished. These future study bears no relationship to the present study. Your 
signature below will allow for the specimen to be stored in a central specimen bank 
with the possibility that it may be used in future tests. The future tests may not 
directly benefit you, but may provide important medical knowledge. 
I agree for you to store the specimen blood sample I have donated for doing special 
research tests in future.  [  ] 
 
 
(vi) 
 
 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________         Signature:  
 
 
 
 
 
 
 
Or 
 
 
 
 
 
 
 
 
 
Representative: _________________ 
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________ 
 
 
Signature of the Investigator: ________________________ 
 
Date: _____/_____/______ 
 
Study Investigator’s Name: _________________________ 
 
 
Signature (or) thumb impression of the Witness: ___________________________ 
 
Date: _____/_____/_______ 
 
Name and Address of the Witness: ______________________________ 
 
 PATIENT PROFORMA 
1. Study Title: Human immunodeficiency virus antibody avidity testing to identify recent 
infection among the newly diagnosed HIV-1 infected individuals and the effect of 
antiretroviral therapy on the avidity antibodies – A pilot study 
 
Study number:                                                                                              Date:  
Name:  
Hospital number:  
Date of birth / Age: Sex:  
Address:  
 
State:                                                                                                          Mother tongue:  
Marital Status:  
Occupation:  
History of exposure/ organ transplantation/blood transfusion:  
Any high risk behavior: 
Date of HIV diagnosis:  
History/Diagnosed other infections:  
Sample collected by  
Name:  
Signature: 
HIV-1 infected individuals 
Study 
No. Age Sex 
Marital 
Status Occupation Exposure 
Transmission 
from Spouse 
High risk 
behaviour State ODn AI 
LAV-1 40 Male Married Mechanic 
Blood 
transfusion No No Jharkhand 2.845 0.92 
LAV-2 40 Female Married Housewife Sexual Yes No 
Andhra 
Pradesh 4.425 0.95 
LAV-3 45 Male Married Business Sexual No Yes 
Andhra 
Pradesh 3.12 0.98 
LAV-4 45 Male Married Driver Sexual No Yes 
Andhra 
Pradesh 3.422 0.90 
LAV-5 40 Female Married Housewife Sexual Yes No 
Andhra 
Pradesh 3.318 0.99 
LAV-6 30 Male Married Artist Sexual Yes No Tamil Nadu 3.595 0.96 
LAV-7 30 Female Married Housewife Sexual Yes No Bihar 4.464 1.10 
LAV-8 38 Female Married Labourer Sexual Yes No Tamil Nadu 0.807 0.34 
LAV-9 30 Female Married Housewife Sexual Yes No West Bengal 3.675 1.24 
LAV-10 39 Male Married Supervisor Sexual No Yes Tamil Nadu 3.916 0.86 
LAV-11 43 Female Married Housewife Sexual Yes No West Bengal 3.561 0.93 
LAV-12 46 Male Married Business Sexual Yes No West Bengal 2.927 0.97 
LAV-13 40 Female Married Housewife Sexual Yes No West Bengal 2.272 0.85 
LAV-14 25 Male Married Driver Sexual No Yes Bihar 4.083 1.02 
LAV-15 22 Female Married Housewife Sexual Yes No Bihar 3.433 1.01 
LAV-16 44 Female Married Nurse Sexual Yes No West Bengal 4.228 1.10 
LAV-17 26 Male Married Labourer Sexual No Yes Tamil Nadu 3.924 1.12 
LAV-18 29 Female Married Housewife Sexual Yes No Manipur 4.503 1.07 
LAV-19 40 Male Married Business Sexual No Yes Manipur 5.07 0.84 
LAV-20 42 Male Married Labourer Sexual No Yes Uttar Pradesh 4.972 1.03 
LAV-21 40 Female Married Housewife Sexual Yes No Uttar Pradesh 4.473 1.06 
LAV-22 35 Male Married Mechanic Sexual No Yes West Bengal 4.126 1.07 
LAV-23 23 Female Married Housewife Sexual Yes No West Bengal 4.766 1.27 
LAV-24 35 Female Married Housewife Sexual Yes No 
Andhra 
Pradesh 3.917 1.11 
LAV-25 25 Male Married Driver Sexual No Yes Jharkhand 5.293 1.03 
LAV-26 20 Female Married Housewife Sexual Yes No Jharkhand 4.81 1.06 
LAV-27 42 Male Married Labourer Sexual No Yes Tamil Nadu 4.463 0.97 
LAV-28 45 Male Married Tea shop worker Sexual Yes No 
Andhra 
Pradesh 2.097 0.88 
LAV-29 47 Male Married Farmer Sexual No Yes Tamil Nadu 2.914 1.06 
LAV-30 22 Female Widow Housewife Sexual Yes No Tamil Nadu 3.702 0.96 
LAV-31 68 Male Married Business Sexual No Yes Jharkhand 1.354 0.59 
LAV-32 52 Male Married 
Government 
employee Sexual Yes No Chhattisgarh 5.509 1.01 
LAV-33 53 Female Widow Labourer Sexual No Yes Tamil Nadu 2.991 0.94 
LAV-34 42 Male Single Labourer Sexual No Yes Tamil Nadu 4.577 1.09 
LAV-35 41 Female Married Housewife Sexual Yes No Tamil Nadu 3.115 0.85 
LAV-36 37 Male Married Carpenter Sexual No Yes West Bengal 3.409 1.11 
LAV-37 48 Male Married Electrician Sexual No Yes Chhattisgarh 4.063 1.00 
LAV-38 35 Female Married Housewife Sexual Yes No Chhattisgarh 4.722 1.12 
Study 
No. Age Sex 
Marital 
Status Occupation Exposure 
Transmission 
from Spouse 
High risk 
behaviour State ODn AI 
LAV-39 33 Male Single Business Sexual No Yes West Bengal 5.463 1.03 
LAV-40 51 Male Married Ex BSI Sexual No Yes Assam 3.22 1.02 
LAV-41 47 Male Married Hotel labourer Sexual No Yes Tamil Nadu 2.914 1.08 
LAV-42 49 Male Married Farmer Sexual No Yes Tamil Nadu 3.277 0.99 
LAV-43 36 Female Married Housewife Sexual Yes No Tamil Nadu 0.166 0.55 
LAV-44 51 Male Married Labourer Sexual No Yes Tamil Nadu 3.089 0.99 
LAV-45 31 Female Married Housewife Sexual Yes No Tamil Nadu 2.629 0.95 
LAV-46 38 Male Married Auto consulting Sexual No Yes West Bengal 4.851 1.09 
LAV-47 42 Female Married Housewife Sexual Yes No Jharkhand 4.763 1.07 
LAV-48 39 Male Married Business Sexual No Yes 
Andhra 
Pradesh 0.353 0.37 
LAV-49 39 Male Married Salesman Sexual No Yes Assam 4.795 0.90 
LAV-50 26 Male Married Tailor Sexual No Yes West Bengal 4.927 1.04 
LAV-51 30 Female Widow Housewife Sexual Yes No Tamil Nadu 4.726 0.95 
LAV-52 55 Male Married Not known Sexual No Yes 
Andhra 
Pradesh 5.153 0.92 
LAV-53 42 Male Married Labourer Sexual No Yes Tamil Nadu 4.571 1.01 
LAV-54 58 Male Married Business Sexual Yes No 
Andhra 
Pradesh 2.699 1.04 
LAV-55 34 Female Married Housewife Sexual Yes No 
Andhra 
Pradesh 0.845 0.48 
LAV-56 35 Male Married Farmer Sexual No Yes Tamil Nadu 3.766 1.05 
LAV-57 45 Male Married 
Government 
employee Sexual No Yes Tamil Nadu 3.355 0.95 
LAV-58 40 Female Married Nil Sexual Not sure No Tamil Nadu 3.845 0.91 
LAV-59 36 Male Married Business Sexual No Yes West Bengal 2.845 0.92 
LAV-60 43 Female Married Housewife Sexual Yes No Tamil Nadu 3.582 1.04 
LAV-61 47 Male Married Tailor Sexual No Yes Tamil Nadu 3.9 1.03 
LAV-62 40 Male Married Labourer Sexual No Yes Karnataka 3.601 1.03 
LAV-64 37 Male Married Farmer Sexual No Yes Tamil Nadu 3.497 0.97 
LAV-65 48 Male Married Hotel Business Sexual No Yes 
Andhra 
Pradesh 3.884 1.04 
LAV-66 30 Male Married Labourer Sexual No Yes West Bengal 3.998 0.91 
LAV-67 44 Female Married Labourer Sexual Yes No 
Andhra 
Pradesh 3.871 0.85 
LAV-68 39 Male Married Business Sexual No Yes Uttar Pradesh 5.275 0.94 
LAV-69 44 Male Married Farmer Sexual No Yes 
Andhra 
Pradesh 3.114 0.94 
LAV-70 33 Female Married Housewife Sexual Yes No 
Andhra 
Pradesh 3.917 0.96 
LAV-72 30 Female Married Housewife Sexual Yes No 
Andhra 
Pradesh 3.993 0.98 
LAV-73 43 Male Married Farmer Sexual No Yes Tamil Nadu 2.059 0.85 
LAV-74 22 Male Single Army Sexual No Yes Tamil Nadu 2.217 0.84 
LAV-75 41 Male Married Hotel labourer Sexual No Yes Tamil Nadu 3.863 1.09 
LAV-76 30 Female Married Housewife Sexual Yes No 
Andhra 
Pradesh 2.541 0.95 
LAV-77 38 Male Married Auto driver Sexual No Yes Jharkhand 2.286 0.81 
LAV-78 45 Female Married Farmer Sexual Yes No Tamil Nadu 3.42 0.97 
LAV-79 48 Female Married Housewife Sexual Yes No Tamil Nadu 3.096 0.95 
HIV-1 infected Individuals 
 
Study 
No. Age Sex 
Marital 
Status Occupation Exposure 
Transmission 
from Spouse 
High risk 
behaviour State ODn AI 
LAV-80 46 Male Married Mechanic Sexual No Yes 
Andhra 
Pradesh 3.71 1.18 
LAV-81 30 Female Married Labourer Sexual Yes No Tamil Nadu 3.832 1.01 
LAV-82 45 Male Single Farmer Sexual No Yes Tamil Nadu 2.75 0.91 
LAV-83 46 Male Married Labourer Sexual No Yes Tamil Nadu 3.534 0.95 
LAV-84 42 Female Married Housewife Sexual Yes No 
Andhra 
Pradesh 2.966 0.81 
LAV-85 42 Female Married  Housewife Sexual No Yes Jharkhand 2.561 0.96 
LAV-86 50 Male Married Labourer Sexual No Yes Tamil Nadu 3.339 0.90 
LAV-87 55 Female Married Housewife Sexual Yes No Jharkhand 3.908 1.04 
LAV-88 37 Male Married Electrician Sexual No Yes West Bengal 4.03 0.97 
LAV-89 35 Male Married Labourer Sexual No Yes West Bengal 3.842 1.06 
LAV-90 51 Male Married Police Sexual No Yes Tamil Nadu 3.822 1.06 
LAV-91 43 Male Married Labourer Sexual No Yes Tamil Nadu 2.111 0.73 
LAV-92 36 Female Married Housewife Sexual No Yes Tamil Nadu 3.272 0.90 
LAV-93 38 Female Married Housewife Sexual Yes No Tamil Nadu 3.925 1.04 
LAV-94 32 Female Married Housewife Sexual Yes No Jharkhand 4.068 1.01 
LAV-95 30 Female Married Housewife Sexual Yes No West Bengal 3.278 1.17 
LAV-97 50 Female Married Housewife Sexual Yes No Jharkhand 2.148 0.98 
LAV-98 50 Female Married Housewife 
Blood 
transfusion No No Tamil Nadu 1.629 1.06 
LAV-99 27 Female Married Housewife Sexual Yes No Tamil Nadu 3.475 1.02 
LAV-100 32 Male Married Business Sexual No Yes Tamil Nadu 3.518 0.98 
LAV-101 58 Female Married Housewife Not known Not known No Tamil Nadu 3.874 1.11 
LAV-102 36 Female Married Labourer Sexual Yes No Tamil Nadu 2.702 0.87 
LAV-103 53 Male Married Labourer Sexual No Yes 
Andhra 
Pradesh 3.607 1.01 
LAV-104 32 Male Married Driver Sexual No Yes Jharkhand 0.183 0.16 
LAV-105 39 Male Married Service Sexual No Yes West Bengal 4.743 1.07 
LAV-106 41 Female Married Labourer Sexual Yes No 
Andhra 
Pradesh 3.897 0.92 
LAV-107 48 Male Married Labourer Sexual No Yes Jharkhand 4.595 1.04 
LAV-108 26 Male Married Teacher Sexual No Yes Tamil Nadu 3.717 0.94 
LAV-109 49 Male Married Business Sexual No Yes West Bengal 4.221 0.91 
LAV-110 35 Female Married Labourer Sexual Yes No Tamil Nadu 0.974 0.69 
LAV-111 40 Male Married Business Sexual No Yes Jharkhand 4.579 1.09 
LAV-112 27 Female Married Housewife Sexual Yes No Bangladesh 4.263 0.91 
LAV-113 33 Male Married Labourer Sexual No Yes Tamil Nadu 3.25 0.97 
LAV-114 29 Male Single Private Job Sexual No Yes Tamil Nadu 3.654 1.03 
LAV-115 48 Male Married Driver Sexual No Yes Tamil Nadu 4.474 1.00 
LAV-116 36 Male Married Business Sexual No Yes Bihar 4.839 0.97 
LAV-117 39 Female Married Housewife Sexual Yes No Jharkhand 0.612 0.54 
LAV-118 42 Female Married Housewife Sexual Yes No 
Andhra 
Pradesh 4.626 1.00 
LAV-119 65 Female Married Housewife Not known No No Tamil Nadu 5.204 0.98 
LAV-120 42 Male Married Labourer Sexual No Yes Jharkhand 4.302 0.91 
 
 HIV-1 infected Individuals 
  
 
S. No Age Sex Marital Status Occupation Exposure 
Transmission 
from Spouse 
High risk 
behaviour State ODn 
1 25 Male Married Painter No No No Tamil Nadu 0.036 
2 38 Male Married Agriculture Sexual No Yes Bihar 0.104 
3 34 Female Widow Housewife Sexual Yes No Karnataka 0.050 
4 29 Male Married Driver No No No Andhra Pradesh 0.043 
5 25 Male Married Painter No No No Tamil Nadu 0.053 
6 39 Male Married Not known Sexual Yes No Andhra Pradesh 0.068 
7 36 Female Married Housewife Sexual Yes No Tamil Nadu 0.075 
8 42 Female Married Housewife Sexual Yes No Tamil Nadu 0.083 
9 54 Female Married Housewife Sexual Yes No Kerala 0.055 
10 24 Male Single Painter No No No Tamil Nadu 0.062 
11 22 Male Single Student No No No Andhra Pradesh 0.069 
12 48 Female Single Housewife Sexual Yes No Tamil Nadu 0.044 
13 25 Female Single Tailor No No No Tamil Nadu 0.053 
14 25 Female Married Housewife Sexual Yes No West Bengal 0.070 
15 30 Female Married Housewife Sexual Yes No Assam 0.057 
16 40 Male Married Mechanic No No No Tamil Nadu 0.099 
17 32 Female Married Housewife Sexual Yes No Andhra Pradesh 0.036 
18 33 Female Married Housewife Sexual Yes No Tamil Nadu 0.066 
19 60 Female Married Housewife No No No Tamil Nadu 0.078 
20 18 Female Single Student No No No Tamil Nadu 0.041 
21 60 Male Married Labourer No No No Tamil Nadu 0.066 
22 30 Female Married Labourer No No No Tamil Nadu 0.091 
23 55 Male Married Business Sexual No Yes Tamil Nadu 0.080 
24 24 Female Married Housewife No No No Tamil Nadu 0.053 
25 29 Female Single DME Engineer No No No Tamil Nadu 0.072 
26 60 Male Married Labourer No No No Andhra Pradesh 0.199 
27 33 Male Married Farmer No No No Tamil Nadu 0.095 
28 33 Male Married Electrician No No No Tamil Nadu 0.037 
29 26 Female Divorcee Housewife No No No Tamil Nadu 0.039 
30 35 Female Married Housewife Sexual Yes Nil Tamil Nadu 0.077 
31 58 Male Married Salesman Sexual No Yes Jharkhand 0.064 
32 29 Male Married Driver No No No Tamil Nadu 0.053 
33 36 Female Married Textile worker No No No Tamil Nadu 0.051 
HIV negative controls 
S. No Age Sex Marital Status Occupation Exposure 
Transmission 
from Spouse 
High risk 
behaviour State ODn 
34 27 Female Married Housewife No No No Tamil Nadu 0.093 
35 40 Female Married Teacher Sexual Yes No Tamil Nadu 0.060 
36 40 Female Married Housewife Sexual Yes No Jharkhand 0.114 
37 45 Female Married Housewife No No No Tamil Nadu 0.050 
38 36 Male Single 
Computer 
Technician 
No No No 
Tamil Nadu 0.097 
39 39 Female Married Housewife Sexual Yes No Tamil Nadu 0.050 
40 44 Female Married Housewife Sexual Yes No Tamil Nadu 0.038 
 
HIV negative controls 
